IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021  
  
 
 A Phase 1b/2 Study of TP- 0903 in Patients with Acute Myeloid Leukemia and 
FLT3 mutations  
 
 
Principal investigator (PI):  
Uma Borate, MD  
1800 Cannon Drive  
Lincoln Tower 1120E   
Columbus, OH 43210 
Phone: 614 -293-3316 
Fax: 614 -293- 6050 
 
Sponsor: The Ohio State University  
1 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021  
  
 
  
No 
 Yes 
AlloHSCT 
(TP-0903 to be discontinued 
one week prior to admission)  
TP-0903 maintenance  
(Continue until loss of 
response/clinical benefit)  
Transplant Eligible?  
(for patients achieving CR/CRh/MLFS)  Synopsis  
We propose a phase 1b/2 study of TP -0903 in AML patients with FLT3 mutations. The study will include 
non-intensive ther apy, using TP -0903 monotherapy for relapsed/refractory  patients.  
TREATMENT PLAN  
 
TP-0903 MONOTHERAPY FOR AML PATIENTS WITH FLT3 MUTATIONS  AND RELAPSED/REFRACTORY 
DISEASE  
AML patients with FLT3 mutations and relapsed/refractory disease are eligible to receive TP -0903, at a 
starting dose of 50 mg daily as a single agent for days 1 -21 of a 28-day cycle. If the 50 mg dose does not 
meet the tolerability criteria, a lower dose level of 37 mg daily as a single agent for days 1 -21 of a 28-day 
cycle will be considered.  
Dose Level  TP-0903 (D1 -21) 
(mg/day PO)  
-1 25 
0 37 
1 50 
Patients may continue treatment indefinitely for as long as clinical benefit is achieved per the 
investigator’s judgment. Bone marrow examinations for disease response assessment will be mandated after the first cycle and at the end of treatment. Subsequent bone marrow examinations may be 
completed at the discretion of the treating physician.  
Schema:  
 
 
 
 
 
Clinical or hematologic  response  No clinical or hematologic response  
  
 
Off Treatment  TP-0903 days 1-21 
of 28 day cycle 
(up to 4 cycles)  
2 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 
 
 
Study Objectives  
Primary Objectives  
• To determine  a tolerable  dose  of TP-0903 monothera py for relapsed/refractory  patients 
with FLT3  AML.  
• To determine the complete remission (CR) or complete remission with partial 
hematologic recovery (CRh) rate following induction therapy with TP -0903 in 
relapsed/refractory patients with FLT3  AML.  
Secondary  Objectives  
• To determine the toxicity profile of TP -0903 monotherapy . 
• To determine disease -free survival for patients achieving CR/CRh.  
• To determine overall survival for patients.  
• To determine the proportion of patients who go to transplant. 
Exploratory Objectives  
• To conduct pharmacokinetic studies of TP-0903 monotherapy . 
• To examine  changes  in circulating AXL,  Gas6,  FLT3  ligand,  and other 
cytokines/chemokines by  TP-0903. 
• To determine the impact of TP -0903 on the inhibition of kinase signaling (AXL, FLT3, 
STAT5, AURKA), and metabolomics in AML  cells. 
• To determine  differentially expressed  genes  in bone  marrow  stromal cells  and AML cells 
upon TP -0903 treatment.  
• To examine sensitivity and resistance patterns associated with TP-0903 by genomic, 
epigenomic, and transcriptomic  profiling.  Abbreviations: AlloHSCT , allogeneic hematopoietic stem cell transplant; CR, complete remission; CRh, 
complete remission with incomplete count recovery; MLFS, morphologic leukemia free state 
3 of 59
   
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Abbreviations  
 
Acronym  Definition  
AE adverse event  
AST aspartate aminotransferase  
BM Bone marrow  
BSA body surface area  
BUN  blood urea nitrogen  
CR complete response  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT dose -limiting toxicity  
ECG 
FLT3  Electrocardiogram  
Fms-like tyrosine kinase 3  
G-CSF granulocyte -colony stimulation factor  
GI gastrointestinal  
IND Investigational New Drug [Application]  
IV 
JAK2  intravenous  
Janus kinase 2  
kD kilodalton (molecular weight)  
MR minimal response  
MTD  maximum tolerated dose  
NS not specified  
ORR  overall response rate  
OS overall survival  
p21 cyclin dependent kinase (CDK4) inhibitor protein of 21K molecular  
weight  
P2RD  phase 2 recommended dose  
p53 tumor suppressor gene/protein of 53K molecular weight, TP53  
PBMCs  peripheral blood mononuclear cells  
PD progressive disease  
PDn pharmacodynamics  
PI3K  phosphoinositol  triphosphate kinase  
PK pharmacokinetics  
PO per os (oral)  
PR partial response  
QOD  every other day dosing  
QODx3  every other day dosing for 3 doses (over 5 days)  
QT interval  the interval between Q and T waves of the electrocardiogram  
QTc interval  corrected QT interval  
RBC red blood cell  
SAE serious adverse event  
SD stable disease  
TIW three times weekly  
4 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Table of Contents
Synopsis  ...................................................................................................................................................... 2 
Study  Objectives  ......................................................................................................................................... 3 
Abbreviations ................................................................................................................................ .............  4 
1. Background and Rationale ...................................................................................................................... 8 
1.1 AML  ............................................................................................................................................................ 8  
1.2 FLT3 mutations and targeted therapies  in AML  ......................................................................................... 8  
1.3 Mechanisms of resistance to  FLT3  inhibitors ............................................................................................. 9  
1.4 Co-occurring baseline and acquired somatic mutations with FLT3 -ITD during  TKI therapy  ...................... 9  
1.5 Axl and Gas6 in AML biology and TKI resistance  ...................................................................................... 1 0 
1.6 FLT3 -ITD+ AML cell metabolic adaptations to  FLT3  inhibition  ................................................................. 11  
1.7 Summary of TP -0903  preclinical studies .................................................................................................. 11  
1.8 Summary of  clinical  studies ...................................................................................................................... 18 
1.9. Rationale and Hypothesis ........................................................................................................................ 19 
2. Patient  Selection  ................................................................................................................................ ... 20 
2.1. Eligibility Criteria ..................................................................................................................................... 2 0 
2.2. Exclusion  Criteria ..................................................................................................................................... 2 1 
2.3. Inclusion of Women and Minorities ........................................................................................................ 2 1 
3. Treatment  Plan  .................................................................................................................................... 22 
3.1. Duration of Follow -up ............................................................................................................................. 2 3 
3.2. Recommended supportive care treatment and special considerations……………………………………………….23  
3.2.1 Nausea……….……………………………………………………………………………………………………………….…………….23  
3.2.2 Diarrhea ……….…………………………………………………………………………………………………………….…………….23  
4. Definition of Dose Limiting Toxicity (DLT)/Dosing Delays and Treatment  Modifications ......................... 23 
4.1. Definition of Dose Limiting Toxicity (DLT)  ............................................................................................... 2 3 
4.2. Dosing Delays/Dose Modifications .......................................................................................................... 24 
4.2.1 Dose Dela ys/ Dose Modifications for DLTs ............................................................................................ 24 
4.2.1.1 Non -hematologic DLT  ......................................................................................................................... 24 
4.2.1.2 Hematologic DLT  ................................................................................................................................ 25 
4.2.2 Dose Delays/ Dose Modifications for Non- DLTs  ................................................................................... 25 
4.2.2.1 Induction  ............................................................................................................................................. 25 
4.2.2.2 Maintenance  ...................................................................................................................................... 25 
4.3 General Administration Guidelines  .......................................................................................................... 26 
5 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 4.3.1 Missed or  Vomited  Doses  ................................................................................................................. 26 
5. Safety and  Reporting Requirements  ..................................................................................................... 26 
5.1. Assessment  of Safety  ............................................................................................................................... 26 
5.2. Definitions  ............................................................................................................................................... 26 
5.2.1.  Adverse Events (AE)  ......................................................................................................................... 26 
5.2.2.  Serious Adverse Event ...................................................................................................................... 27  
5.2.3.  Severity ............................................................................................................................................ 2 8 
5.2.4.  Suspected Adverse Reaction ............................................................................................................ 28 
5.2.5.  Unexpected ...................................................................................................................................... 2 9 
5.3. Documenting and Reporting of Adverse Events (AEs) and Serious Adverse  Events (SAEs)  .................... 28 
5.3.1.  Adverse Event  Reporting Period  ...................................................................................................... 28 
5.3.2.  Assessment of Adverse Events ......................................................................................................... 29 
5.4. Procedures for Reporting Drug Exposure During Pregnancy and  Birth  Events ....................................... 30 
5.5. Expedited Reporting Requirements for Serious  Adverse Events  ............................................................ 30  
5.6. Routine Adverse  Event Reporting ........................................................................................................... 3 1 
5.7. Type and Duration of Follow- up of Patients after Adverse Events ......................................................... 31  
5.8. Data Safety Monitoring Plan  (DSMP)  ...................................................................................................... 31  
6. Pharmaceutical  Information  .................................................................................................................. 32 
6.1 Drug information  ...................................................................................................................................... 3 2 
6.1.1 Drug substance  and description ........................................................................................................ 3 2 
6.1.2 Preclinical absorption, distribution, metabolism,  and excretion ...................................................... 32  
6.1.2.1  Drug transporter effects ................................................................................................................ 32  
6.1.2.2  CYP450  effects ............................................................................................................................... 3 3 
6.1.2.3  Liver microsome  stability ............................................................................................................... 3 3 
6.1.2.4  Serum albumin  binding .................................................................................................................. 3 3 
6.1.2.5  pKa of TP0903  ................................................................................................................................ 33  
6.1.2.6  pH-dependent solubility of TP0903  ............................................................................................... 33  
6.2 Potential drug -drug interactions and  concomitant medications ........................................................ 33  
6.3 Prohibited therapies ............................................................................................................................. 3 4 
6.4 Study Drug  Management .......................................................................................................................... 3 4 
6.4.1    TP-0903 Drug  Product ................................................................................................................... 3 4 
6.4.2 Study Drug Dispensing  and Accountability ................................................................................... 34  
6.4.3      Storage at  Study Center ................................................................................................................ 34  
6.4.4 Accountability and Destruction of Investigational Medicinal Product ...............................................
 34 
6 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 6.4.5 Drug Administration  ........................................................................................................................... 3 5 
7 Measurement  of Effect  ................................................................................................................................ 35 
7.1. Response Criteria ..................................................................................................................................... 35  
8 Correlative  Studies ......................................................................................................................................  38 
9 Study  Calendars  ................................................................................................................................ ........... 41 
TP-0903 monotherapy, (Cycle  1 only) ............................................................................................................ 4 1 
TP-0903 monotherapy (Cycles 2-4 and maintenance) ................................................................................... 4 3 
10 Statistical  Considerations .................................................................................................................... 45 
11 Ethics and  Regulatory Requirements  ...................................................................................................  47 
11.1. Patient Protection  ................................................................................................................................. 4 7 
11.2. Patient Information  ............................................................................................................................... 4 7 
11.3. Informed Consent  ................................................................................................................................. 4 7 
11.4. Ethics Board  Approval ........................................................................................................................... 4 8 
12 Documentation, Record Access and Maintenance of Study  Records  .................................................... 48 
12.1. Documentation of  Patient’s  Participation  ............................................................................................. 4 8 
12.2. Source Documentation .......................................................................................................................... 4 8 
12.3. Regulatory Requirements ...................................................................................................................... 4 8 
12.4. Patient Confidentiality and Access to Source  Data/Documents ...........................................................  48 
12.4.1.  Patient Identification ..................................................................................................................... 4 8 
12.5. Confidentiality of  the Study ................................................................................................................... 4 9 
12.6. Registration of Clinical Trial  ................................................................................................................... 4 9 
12.7. Maintenance of  Study Records  ............................................................................................................. 4 9 
13 Administrative Procedures  .................................................................................................................. 50 
13.1. Protocol Deviations and Violations ....................................................................................................... 50 
13.2. Premature Discontinuation of  the Study .............................................................................................. 50 
14 References  ..........................................................................................................................................  50 
Appendix A. Cytochrome P450 Drug  Interaction  Table  ............................................................................... 54 
 
7 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 
1. Background and Rationale  
1.1 AML 
 
Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by genetic and epigenetic 
alterations that lead to a block in granulocyte differentiation and accumulation of leukemic blasts in blood and bone marrow (BM). Nonrandom chromosomal  abnormalities (e.g., deletions, translocations) are 
identified in approximately 55% of all adult primary AML patients and are thought to provide the most significant information regarding prognosis and responsiveness to intensive therapy as well as to dir ect 
initial treatment strategies, including allogeneic transplantation in first CR[2]; however, approximately half of AML diagnoses are associated with a normal karyotype and highly variable disease outcomes[2, 3]. Over the past two decades, advances in mo lecular diagnostics have improved our understanding of AML 
biology and has contributed remarkably to refining overall prognosis, particularly in patients with cytogenetically normal AML (CN-AML) [4].  
 With current treatment strategies, approximately 40% of AML patients achieve long -term remission.  Of 
those  patients who  relapse, only  a fraction  successfully undergo  salvage  treatment followed by allogeneic 
stem cell transplant with curative intent. For older adults (>65 years), the prognosis is even more dism al 
as patients in this age group often have poor -risk disease that is associated with adverse or complex 
karyotypes. Furthermore, the presence of comorbid conditions and lack of suitable donors render these 
patients ineligible for aggressive treatment (i.e., allogeneic stem cell transplant). Even with adaptation  of 
cytogenetically  risk-stratified  therapies,  20%  to 30%  of AML  patients  never achieve CR, and greater  than  
50% of patients  who  achieve CR subsequently  experience very early disease  relapse. The lack of significant 
advances in the treatment of AML in adults highlights the need for development of novel therapeutic  
strategies, particularly those  directed against  molecular  targets  that are known to be involved in disease  
pathogenesis. 
1.2 FLT3 mutations and targeted therapies in AML  
 Mutations in the fms -like tyrosine kinase 3 ( FLT3 ) gene were one of the first molecular abnormalities  to 
be described in AML.  FLT3 is a type  3 receptor  tyrosine  kinase expressed on normal  bone marrow 
progenitor cells; its expression is normally lost with maturation of these progenitors[5]. Binding of FLT3 
ligand to FLT3 activates the FLT3 signal transduction pathway, which works in concert with other signaling pathways (including STAT, MAPK and PI3K) to regulate hematopoietic cell maturation and growth[5, 6]. 
FLT3 is expressed on AML cells in at least seventy -percent of cases, and approximately one third of AML 
patients harbor activating mutations of FLT3 , including internal tandem duplications (ITDs) in  25% and 
tyrosine  kinase domain (TKD) point  mutations  in 5% [5, 7, 8], resulting in constitutive  activation of FLT3  
signaling.  
 
The presence of the FLT3-ITD mutation has a well -recognized adverse prognostic impact on disease 
outcomes,  with  short disease -free  survival  following standard  AML  chemotherapy  [9-11].  As such, 
molecularly targeted therapies directed at inhibiting FLT3 signaling are an attractive treatment option to 
improve disease outcomes in this ill-fated subset of  patients.  
A number of FLT3 tyrosine kinase inhibitors  (TKIs) have been evaluated, initially as single agents, then in 
8 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 combination with chemotherapy, to assess AML response and impact on outcomes in AML patients who 
carry FLT3 mutations. Phase I/II trials of single-agent lestaurtinib (CEP 701), midostaurin (P KC 412) and 
sorafenib, demonstrated that these agents were generally well tolerated and upward of seventy -percent 
of patients achieved some degree of hematologic improvement, as evidenced by reduction in blood 
and/or bone marrow blasts [12 -15]. However, wi th single-agent therapy thes e responses were incomplete 
and transient, leading to evaluation of these agents in combination with standard chemotherapy regimens. A phase III trial of midostaurin in combination with chemotherapy for FLT3 -ITD+ AML was 
complet ed and showed prolonged overall and event -free survival, which led to FDA approval in this 
disease [16]. These “first -generation” FLT3 inhibitors may not be optimal due to high plasma protein 
binding, [17] significant toxicities, and lack of potent FLT3 inhibition [18 -22]. “Second - generation” FLT3 
inhibitors with more selective and potent FLT3 inhibition, including quizartinib, crenolanib and gilteritinib 
are in phase II and III clinical evaluation alone and in combination with chemotherapy in FLT3-ITD + 
AML[23].  
1.3 Mechanisms of resistance to FLT3  inhibitors  
 
One of the most well described mechanisms of acquired resistance to FLT3 TKIs is the development  of 
secondary  FLT3  TKD mutations,  primarily  at residues  D835 and F691.  TKD point  mutations alters the 
conformation of the kinase which deters proper binding of the inhibitors. Docking models suggest  that 
TKIs bind  to the ATP-binding pocket  and DFG  residues in a region  of the activation  loop  in the kinase 
domains. Substitution  of amino  acid residues  within  the activation  loop  shift  the orientation of DFG residues 
to a “DFG -out” motif. Binding of TKIs with type II properties are perturbed by this substitution mutation, 
whereas TKIs with type I or type II properties have altered binding to FLT3 mutations at th e gatekeeper 
residue, F691, in the ATP -binding pocket [24]. Currently, sorafenib and quizartinib are type II FLT3 TKIs 
used clinically in AML that have been shown to be susceptible to resistance conferring TKD mutations [24 -
26]. While FLT3 D835 mutations h ave not been shown to emerge during gilteritinib and crenolanib 
treatment (type I TKIs), clinical studies have shown patients develop F691 gatekeeper mutations that 
confer drug resistance [27, 28]. Pharmacokinetic studies have revealed that some FLT3 TKIs have 
suboptimal properties such as high plasma protein binding and/or a short half -life, which can be 
associated with subtherapeutic plasma concentrations and insufficient cytotoxic effects. For example, the  
FLT3 TKI crenolanib must be  administered three  times  daily to remediate such  shortcomings[29]. The lack 
of patient medication adherence to strict drug regimens can become an added hurdle to achieve adequate drug response. Nonetheless,  FLT3 inhibition  remains  an important  therapeutic target that is the subject of 
ongoing studies. 
1.4 Co-occurring baseline and acquired somatic mutations with FLT3 -ITD during TKI  therapy  
 
Recent studies have reported the co -occurrence of mutations with FLT3 -ITD, such as NPM1 , DNMT3A , 
WT1 , IDH1/2 , and TET2 , that likely impact pr ognosis and clinical outcomes.[30, 31] Using a targeted  gene  
panel,  WES, and deep  amplicon  sequencing of FLT3 TKD1  (exon  17) and TKD1  (exon  20), we determined the 
mutations that co -occurred with FLT3-ITD in patients prior to receiving crenolanib as a single agent, and 
compared the gene profiles between different crenolanib response groups. Higher frequencies of IDH1/2 
and TET2 mutations, among others, were present in poor responders versus crenolanib good  responders. 
We did not observe  an association  of FLT3  mutation  status  (ITD,  TKD or both) with crenolanib response, 
although 1 patient harboring a baseline FLT3 F691L mutation was a poor responder. Paired samples (pre -
9 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 TKI/during ≥ 28 days of TKI) from 14 patients were profiled for FLT3 mutations. FLT3 F691L mutations 
arose in 2 patients. Further profiling revealed that TET2 , IDH1/2 , and NRAS mutations were not cleared 
during treatment, and new mutations in IDH1 and NRAS emerged in several patients during crenolanib 
treatment. A recent analysis by next generation sequencing of paired samples (pre-TKI/TKI progression) 
from 16 patients receiving gilteritinib (type I TKI) treatment revealed the emergence of new mutations 
including FLT3 F691L (N=3) and mutations in IDH2 ( N=1) and NRAS (N=4).[32] These data highl ight the 
genomic complexity of FLT3 -ITD+ AML and the potential role that baseline and/or acquired co -occurring 
somatic mutations contribute to FLT3 TKI  resistance. 
 
1.5 Axl and Gas6 in AML biology and TKI  resistance 
 
The receptor tyrosine kinase Axl was first discovered 20 years ago and subsequently identified to be 
involved in the pathogenesis of various cancers. Axl, along with Tyro -3 and Mer, are receptor tyrosine 
kinase that belong to the TAM  family of kinases.  TAM  kinases  are involved in a variety of cellular processes 
including cell proliferation and survival, and cell adhesion and migration. The prognostic implications of Axl in AML was initially illustrated in the 1990s and has been reported to be associated with AML 
leukemogenesis  [33]. Several lit erature  reports  have  indicated that Gas6 (growth  arrest  specific 6), an Axl 
ligand, has prognostic implications. In 270 adults with de novo cytogenetically normal AML, patients expressing Gas6 more often failed to achieve a remission and had shorter overal l survival and disease - 
free survival. Recently, the role of Axl in FLT3 -ITD+ AML biology and as a potential therapeutic target has 
been described [34-36]. Axl and FLT3 -ITD interaction was first proposed by Park et al., where 
phosphorylation  of FLT3-ITD  was disrupted  by Axl-Fc (soluble Axl chimeric protein  that binds  to Axl ligand 
abrogating Axl activation) or siRNA targeting of Axl[35]. Axl inhibition by Axl -Fc led to a decrease in 
proliferation of FLT3 -ITD+ AML cells and patient primary blasts due to cell  cycle arrest and apoptosis. 
Further in vivo effects of Axl inhibition by Axl -Fc was demonstrated in a primary human FLT3-ITD+ AML 
xenograft in SCID mice, where there was less human CD45+ cells detected in the Axl -Fc treatment group 
compared to the control -Fc group.  
 Another group evaluated Axl in the context of AML in the tumor microenvironment [36]. They demonstrated that AML cells stimulate bone marrow stromal cells to upregulate Gas6. Upregulation of 
Gas6 fostered AML cell growth and cytarabine d rug resistance through Axl signaling, whereas silencing Axl 
in Gas6 -negative AML cells in the absence of stromal cells did not produce significant effects [36].  
 
The same group further determined the effects of Axl inhibition in FLT -ITD+ AML in combination  with 
chemotherapy. Inhibition  of Axl by BGB324, an Axl TKI undergoing clinical  development, or Axl shRNA with 
concomitant administration with cytarabine or doxorubicin led to additive in vitro anti -leukemic effects. 
Upon silencing Axl, FLT3 -ITD+ MV4 -11 ce lls became more sensitive to doxorubicin compared to control 
group. Conversely, overexpression of Axl led to increased chemo resistance against doxorubicin. When  
primary  AML  cells were  treated concurrently  with  BGB324 and cytarabine,  the combination  exerte d 
additive effects compared to either drug alone. Considering that combination chemotherapy  is utilized as 
the standard of care in managing AML, additive or synergistic effects upon concomitant inhibition of Axl with  AML  gold  standard  chemotherapeutic agents  provides  justification  that Axl inhibitors  in combination 
regimens could potentially be used as a therapeutic approach in treating patients with  FLT3-ITD. 
More specifically, later published work by Park et al identified Axl as a key component of res istance to the 
10 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 FLT3 TKIs, midostaurin and quizartinib[35]. Axl phosphorylation was increased in FLT3 - ITD+ AML cells 
exposed to midostaurin and quizartinib, and inhibition of Axl by TP -0903, the Axl -Fc chimeric protein or 
lentiviral encoding shRNA targetin g Axl in midostaurin-resistant MOLM13 cells, sensitivity to midostaurin 
and quizartinib was restored. While phospho -Axl was detected in FLT3 -ITD+ primary  blast  samples  with 
midostaurin resistance  ex vivo, it was not detected  in blasts that were  sensitive to midostaurin therapy. 
Similar findings were observed in in vivo in a midostaurin -resistant MOLM13 cell line  xenograft  model.  
Mice  were treated  with  either vehicle control,  midostaurin  alone, TP-0903 alone, or the combination of 
midostaurin and TP-0903. Combination therapy prolonged survival in mice compared to either TKI alone. 
As midostaurin received Breakthrough Therapy status from the FDA, identification of resistance 
mechanisms to midostaurin may have serious therapeutic implications for pat ients receiving this agent, 
and therapeutic strategies to circumvent resistance will be  needed. Collectively, these findings indicate 
that upregulation of Axl is involved in resistance to several FLT3 TKIs, and inhibition of Axl is a potential 
approach to counteract FLT3 TKI resistance.  
 
1.6 FLT3 -ITD+ AML cell metabolic adaptations to FLT3  inhibition  
 
Previous studies have demonstrated that FLT3 -ITD+ AML cells display increased glycolysis and central 
carbon metabolism compared to FLT3 wild type cells, supported  by analysis of clinical gene expression 
datasets showing signatures of upregulated glucose metabolism and TCA cycle.[37, 38] Two recent  studies 
have  highlighted  the role of metabolic  adaptations  in response to FLT3  TKI treatment. One group showed 
that FLT3 inhibition with quizartinib impaired glycolysis in MOLM13 and MV411 AML cell lines.[38] By 
performing cellular uptake studies with glucose and glutamine, metabolic flux analysis using U-13C6-
glucose, and gene expression profiling, they showed that quizartinib blocked glucose uptake, but not 
glutamine,  reduced  glucose labeling of glycolytic intermediates, and downregulated  glycolytic enzyme 
gene expression. They concluded that FLT3 -ITD inhibition impairs glycolysis without affectin g glutamine 
metabolism. Another group demonstrated that quizartinib impairs glutamine metabolism in MOLM13 
cells through metabolic flux analysis using 13C,15N-labeled glutamine; quizartinib decreased intracellular 
labeled glutamine and downstream metabolit es (glutamate, α -ketoglutarate)[39]. These studies suggest 
AML  cells undergo  metabolic changes  during  FLT3 inhibitor  treatment,  which we will evaluate  in response 
to TP -0903 treatment in primary patient AML  samples. 
 
1.7 Summary of TP -0903 preclinical studies 
 
TP-0903 is an orally bioavailable inhibitor  of Axl. The chemical  name of TP-0903 is 2-{[5-chloro-2- ({4-[{4-
methylpiperazin-1- yl)methyl]phenyl}amino)pyrimidin-4- yl]amino} -N,N- dimethylbenzene -1- 
sulfonamide mono -tartrate salt . Based on previous reports that Axl is an important mechanism of 
resistance  to FLT3 TKIs and AML -directed chemotherapy,  we were  interested in evaluating TKIs that target 
Axl as a possible therapy against de novo and drug resistant FLT3 -ITD+ AML. Previously, in a screen 
consisting  of 40 kinases, TP-0903 (200 nM) was shown  to inhibit (>50%)  eleven kinases[40].  We evaluated 
the inhibition of these kinases, as well as Axl, by TP -0903 in a binding assay with the resultant Kd values: 
Axl (8.2 nM),  MER  (4.4 nM),  TYRO3  (970 nM),  AURKA  (0.99 n M), CHEK1 (24 nM),  JAK2  (0.2 nM),  ABL1 (1.2 
nM),  IGF1R (56 nM),  CSF1R (16 nM),  PDGFRB  (80 nM),  and VEGFR2  (110 nM).  In a kinase assay, TP-0903 
inhibited Axl with an IC50 value of 4.9 nM. It has been reported that other AXL inhibitors in development 
also ta
rget FLT3[41].  Therefore, we profiled the activity  of TP-0903  against  FLT3 and ITD/TKD  mutants.  TP- 
11 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 0903 had potent binding affinities against  wild type  FLT3  (FLT3-WT)  (Kd = 0.93 nM),  FLT3-ITD  (Kd = 5.6 
nM),      FLT3      TKD    D835 
mutants (Kd = 0.79 - 2.1 
nM), and the double 
ITD/TKD F691L gatekeeper 
mutant  (Kd = 1.9 nM) (Table 
1). For comparison, binding 
affinities clinical candidate 
FLT3 inhibitors including 
gilteritinib, a FLT3/Axl 
inhibitor,    are    shown    in 
Table 1 . In a kinase assay, TP-0903 inhibited FLT3 -ITD and the D835Y mutant with IC50s of 3.9 and 0.12 
nM, respectively.  The observation  that TP-0903 has greater potency  against  FLT3 activation  loop  D835 
mutations suggests that TP -0903 has type I kinase inhibitor properties. These findings provide the 
rationale for further evaluation of TP -0903 in de novo and TKI resistant FLT3 -ITD+ AML.  
We compared the activity of TP -0903 and a series of clinical candidate FLT3 TKIs in Ba/F3 cells 
expressing FLT -ITD and TKD mutants, which many groups including our lab have used to understand the 
impact of different FLT3 mutations on TKI sensitivity [25, 42 -44]. While sorafenib and quizartin ib, were 
resistant to TKD mutations, TP-0903 showed activity against all FLT3 TKD mutations. The latter included the  gatekeeper  F691L  mutation,  which  gilteritinib,  crenolanib,  and  midostaurin  showed  reduced 
sensitivity b y 36-, 32-, 
and 4.8-fold,  
respectively, compared to cells expressing FLT3 - 
ITD ( Figure 1A and 1C). 
In Ba/F3 cells expressing 
FLT3-ITD and TKD single 
and double mutations, 
TP-0903 inhibited the 
phosphorylation of FLT3 and downstream STAT5 
in a dose- dependen t 
manner starting at 
10nM, as assessed by 
western blot (Figure 1B). 
Development of TKD      mutations      are 
major obstacles to FLT3 TKI therapy presented in real clinical settings [24, 25, 42, 45, 46]. Here, in vitro sensitivity testing suggests that TP -0903 could overcome drug resistance from acquired TKD mutations. 
Additionally, TP -0903 has the most potent activity against the gatekeeper F691L mutation, which  current 
FLT3 inhibitors succumb to. TP -0903 was originally designed on an Axl scaffold that do es not clash with 
the Axl gatekeeper residue, Leu620. Given its initial drug design, TP -0903 may bind to F691 substitution 
mutation  to leucine in similar manner  as it does  to L620 in Axl. Based  on these  data,  TP-0903 can be used 
as a strategy to overcome clinically relevant FLT3 TKD mutations reported to  date.  
 
 
 
 
 
 
 
 
 
Table 1 . Inhibition of FLT3 -ITD and TKD  mutants by TP -0903 and other FLT3 TKIs in a 
binding assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 . Effect of TP-0903 and other TKIs in Ba/F3 cells transfected with FLT3 mutants. ( A) 
Cell viability curve. (B ) FLT3 signaling assessed by western blot after 4h of treatment with 
designated concentrations. ( C) FLT3 TKI IC50 values (MTT assay, 72h, N=18). 
12 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 We further evaluated the in 
vitro potency of TP -0903 in the FLT-ITD+ 
AML cell lines MOLM13, MOLM13 -Res, 
and MV4 -11 in a cell viability assay. 
MOLM13 -Res cells are a FLT3 TKI 
resistant progeny of MOLM13 cells that 
harbor a dual ITD/D835Y mutation, that 
were generated in our lab [43]. TP -0903 
had potent anti -leukemic activity in all 
AML cell lines ( Figure 2 ). For 
comparison, IC50 values for other FLT3  
TKIs are shown in Figure 2B . Collectively, our preliminary data indicate that TP -0903 has therapeutic  
potential  in both  de novo and TKI resistant FLT3-ITD+ AML,  by targeting  FLT3 -ITD,  FLT3 TKD mutations,  Axl 
and potentially other kinase targets.  
To determine  if TP-0903 induces  cytotoxicity  in FLT3- ITD+ AML  cell lines, we performed  apoptosis 
and cell cycle assays by annexin -V/DAPI staining and flow cytometry. TP -0903 20nM induced significant 
apoptosis at 24 and 48h of treatment ( Figure 3A and 3B ), and a G2-M cell cycle arrest at 6h and 12 h 
(Figure 3 C ). Consistent with cells undergoing apoptosis, an increase in a sub -G1 peak was observe at 24 
h (Figure 3D). The observed G2-M arrest  is likely related to AURKA  inhibition,  which  is a unique  feature  of 
TP-0903 relative to other clinical candidate FLT3  TKIs.  
 
There are literature reports in FLT3-ITD+ patients where FLT3 TKIs induced terminal myeloid 
Figure 2. Effect of TP -0903 and 
other FLT3 TKIs on cell viability in 
FLT3- ITD+ AML cell lines. (A ) Cell 
viability curve (data are mean ± SEM). ( B) FLT3 TKI IC50 valu es 
(MTT assay; 72h; N=18)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 . TP-0903 induces apoptosis and a G2- M cell cycle arrest  in AML cell lines. (A ) Representative flow 
cytometry measurement of apoptosis using annexin -V and DAPI staining at 48h of treatment. ( B) Quantification 
of annexin- V positive cells at designated treatment times (N=3). (C ) Representative cell histograms aft er 12h of 
treatment. ( D) Quantification of each cell cycle phase is shown at designated treatment time (N=3). 
13 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 differentiation in leukemic blasts. Patients with minimal change in ITD allelic ratios post -quizartinib 
treatment displayed predominantly  mature  neutrophils with very little  wild-type  FLT3 allele [47].  This was 
also observed in sorafenib  treated patients where blast -free bone marrow with normocellular or 
hypercellular marrows had readily detectable FLT3 -ITD. This was further confirmed by in vivo 
transplantation in which sorafenib differentiated FLT3 -ITD+ myeloblasts [45]. With induction o f 
differentiation in blasts as another potential mechanism of action in FLT3 TKIs, we also examined if TP - 
0903 differentiates FLT3-ITD+ AML cells to mature myeloid cells. We first measured CD11b expression in 
AML cell lines via flow cytometry. TP -0903 inc reased CD11b expression to 3 - to 30 -fold at 48 -72h 
compared to DMSO control ( Figure 4A ). In parallel, we measured expression of different genes that are 
expressed in more mature myeloid cells including the granulocyte colony stimulation factor receptor 
(GCSFR) and lysozyme gene using TaqMan Real -Time PCR (RT -PCR). In all FLT3 -ITD+ AML cell lines, GCSFR 
and lysozyme  gene expression was increased by up to 20-fold with  TP-0903 treatment compared  to DMSO 
control  (Figure 4B). Ex vivo treatment  of two FLT3-ITD+  primary  patient blast  samples  with TP-0903 in a 
CFU assay, cells showed morphologic differentiation with multilobulated nuclei compared to DMSO 
control (Figure 4C ). These data indicate that TP -0903 induces differentiation of FLT3 -ITD+ leukemic blasts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 . TP-0903 induces differentiation of FLT3 -ITD+ AML cells.  
(A) Representative histogram of CD11b expression measured by 
flow cytometry shown at 72h (upper panel) and fold -change of 
CD11b expression compared to control at 48h  and 72h (lower 
panel,  n=3).  (B) Increase  in GCSFR  and lysozyme  gene  expression at 
48h and 72h of TP -0903 treatment (RT- PCR, n=6). (C ) Ex vivo 
treatment of two FLT3 -ITD+ patient samples in a CFU assay (upper 
and lower panel) induced morphological  different iation.  
14 of 59
 IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
We assessed the ex vivo activity of TP -0903 in human primary FLT3 -ITD+ AML samples with co - 
occurring mutations including NRAS , IDH1/2 , SMARCA2 , NPM1 , and among others. TP -0903 inhibited the 
viability of patient  samples with  IC50  values ranging from  26.6-67 nM; in comparison,  gilteritinib was 3.5- 
to 35 -fold less potent than TP -0903 with IC50 values ranging from 1.5 105 to 1300 nM ( Figures 5A and 
5B). Other FLT3 TKIs showed much less potent activity in these samples compared to TP -0903. Although 
preliminary, these data suggest that TP -0903 may have activity against clinically relevant TKI -resistance 
conferring co -occurring mutations as described  above.  
15 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 
With positive in vitro and ex vivo data demonstrating antileukemic activity in FLT3 -ITD+ cells, we 
evaluated the in vivo therapeutic potential of TP -0903 in MOLM13-YFP/Luciferase (MOLM13 -Luc+) and 
MOLM13 -RES -Luc+ mouse xenograft models. We performed tolerability studies of TP -0903 in tumor- 
bearing 8 - to 12 -week old female NSG mice (1 million cells administered by tail vein injection) at doses 
ranging from 40 -80 mg/kg administered once daily or daily x 5/week for 3 weeks and determined that 60 
mg/kg was the MTD on these schedules. PK studies performed in mice at TP -0903 60 mg/kg show that 
plasma exposure achieved is in the range observed in patients in the ongoing phase I clinical trial in solid 
tumors (data on fil e at Sumitomo Dainippon Pharma Oncology, Inc. (SDPO) ). For efficacy studies, 
treatment was started on days 7 or  
13 in the MOLM13-Luc+ and MOLM13 -RES- 
Luc+ xenografts, respectively, after a similar level of bone marrow engraftment was documented by bioluminescence imaging 
(Figure 6A ). In both xenograft models, TP - 
0903 delayed the outgrowth of leukemia 
cells (P=0.0015 and 0.0007, respectively) (Figure 6A) and prolonged  survival  by 17 and 
9 days (P<0.0001 and P=0.002, respectively) 
compared to vehicle -treated mi ce ( Figure 
6B). 
In the MOLM13 -Res -Luc+ xenograft 
efficacy study, we collected bone marrow 
and blood  samples  when mice  succumbed  to 
leukemia. Bone marrow samples were enriched for MOLM13 -RES cells by CD45 
selection, RNA was extracted and AXL gene expression was measured  by RT-PCR.  Plasma 
Gas6   was   measured   by   ELISA.   TP-0903 
significantly decreased AXL gene expression in leukemic cells (P=0.0009) ( Figure 7A). High levels of 
circulating Gas6 was observed in vehicle -treated mice, which was significantly reduced in mice treated 
with TP -0903 (P=0.017) ( Figure 7B ). These preliminary data demonstrate that TP -0903 modulates AXL 
expression in leukemia cells and reduces circulating levels of its ligand Gas6 in the in vivo setting. These 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 . Effect of TP -0903 and other FLT3 TKIs on the viability of primary human FLT3 -ITD+ AML samples with co - 
occurring mutations ex vivo . Cell viability curves in (A) patient blast samples and ( B) TKI IC50 values (CellTIter -Glo assay, 72 
h, N=3 -6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 . In vivo activity of TP -0903 in MOLM13- Luc+ and 
MOLM13 -RES-Luc+ xenograft mouse models. ( A) Bioluminescence 
imaging  reported as average radiance. ( B) Survival by Kaplan- 
meier analysis. Black bars depict treatment duration. 
16 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 studies will be incorporated in the clinical pharmacodynamic studies outlined in Aim 2. Combined, our 
preclinical studies demonstrate that TP -0903 has activity in de novo and TKI-resistant FLT3 -ITD+ AML and  
provide the scientific premise to conduct a phase 1b/2 trial  of TP -0903 in patients with FLT3-ITD+ AML. It 
is anticipated that TP-0903 will have  immediate clinical  impact  to circumvent  and treat currently  identified 
clinically relevant FLT3 TKI resistance  mechanisms.  
Given the recent interest in the 
discovery and development of agents to target cancer metabolism, [48] these  studies 
suggest the metabolic changes that occur during FLT3 TKI treatment can be exploited 
therapeutically. However, the exact 
mechanisms leading to metabolic reprogramming are not well described and  it 
is unknown if different FLT3 TKIs induce distinct metabolic responses. To begin to 
address this, we performed gene expression 
analysis      (RNASeq)      of      bone   marrow 
MOLM13 -RES AML cells obtained from mice treated with TP -0903 or vehicle ( Figure 6 ) and determined 
the changes  of genes involved in glutamine and glucose cellular transport and metabolism. TP -0903 
significantly downregulated genes involved in glutamine transport and metabolism ( Figure 8A ). Five of 7 
top downregulated genes in these pathways were: 1 ) three cell mem brane glutamine transporters, 
SLC38A1 (SNAT1),  SLC1A5 (ASCT2),  and SLC7A5 (LAT1);  2) glutamic -pyruvic  transaminase  2 (GPT2),  a 
mitochondrial 
transaminase  that 
converts glutamate→α - 
ketoglutarate; and 3 ) 
asparagine synthetase 
(ASNS), an enzyme that converts aspartate → asparagine coupled to 
the metabolism of 
glutamine → glutamate. Expression changes in these genes were 
validated by RT -PCR 
(Figure 8B ). Expression 
changes in these genes were validated by  RT-PCR 
(Fig 8B ). We confi rmed 
that TP -0903 inhibited 
the uptake of glutamine, which was not observed with gilteritinib ( Fig 8C). 
Fig 8D illustrates a working  model  depicting the pathways  involved in the inhibition  of glutamine transport 
and metabolism by TP -0903. These data provide the scientific rationale to perform metabolomics and 
carbon flux studies in primary patient AML samples in response to TP -0903 treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. TP-0903 impairs glutamine transport/metabolism in a MOLM13- RES-Luc+ 
xenograft model. ( A) Volcano plot for gene expression changes by RNASeq in cells 
from mice treated with TP -0903 (N=5) or vehicle (N=10). ( B) Validation of gene 
expression changes by RT -PCR. P values are from unpaired t -tests, two -sided. ( C) 
TP-0903, but not gilteritinib, inhibits glutamine uptake in HeLa cells. ( C) Model 
depicting pathways  involved in impaired glutamine transport/metabolism  by TP-0903.  
 
 
 
 
 
 
 
 
 
 
Figure 7 . Effect of TP -0903 treatment on ( A) AXL gene expression 
in bone marrow AML cells (by RT -PCR) and ( B) circulating plasma 
Gas6 (by ELISA) in a MOLM13 -RES-Luc+ xenograft mouse model.  
17 of 59
IRB Protocol  Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 1.8 Summary of clinical studies  
The first -in-human phase 1a/1b study with TP -0903, TP -0903-101 (Clinicaltrials.gov identifier: 
[STUDY_ID_REMOVED]) is ongoing in patients with refractory solid tumors. The Phase 1a study is designed to 
identify the maximum  tolerated  dose  (MTD)  and to identify  the safety  profile and recommended  phase  2 
dose of TP-0903.  Once  the MTD  has been  established, 5 additional  cohorts  of up to 20 patients  each  with 
specific tumor  type  will be enrolled at the MTD  in the phase 1b study. TP-0903 is administered once  daily 
for 21 days followed by a 7-day drug-free period for one cycle. Patients are allowed to continue on TP - 
0903 if it shows benefit and is reasonably well tolerated. As of August 2018, adverse events observed in patients treated at the  first 7 dose levels are shown in Table 2. Patients are consistently presenting with 
nausea/vomiting, diarrhea, and anorexia and no DLTs have been observed. Thus far, TP-0903 has been well tolerated  with  no patients  coming  off study  due to drug-related toxicity.  As of March  2019, a flat dose 
of 50 mg daily on days 1-21 of a 28 day cycle is the dose that will be used for future phase 1b expansion cohorts.  
 
  
 
   
 
    
 
    
 
    
 
    
 
    
 
18 of 59
IRB Protocol  Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 Table  2. Treatment -emergent  adverse  events by body  system  and preferred  term  by dosing cohort  (safety population 
and overall). 
 
 
 
1.9. Rationale and Hypothesis  
In biochemical  and cellular assays, we showed that TP-0903 can overcome  drug resistance  from  acquired 
19 of 59
IRB Protocol  Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 FLT3 TKD mutations, including the gatekeeper F691L mutation, which current clinical candidate FLT3 
inhibitors are susceptible to. In ex vivo testing of primary FLT3 -ITD+ leukemia samples, including those 
harboring a TKI-resistance  conferring  FLT3 -ITD/ IDH2  mutation,  TP-0903 was more potent than  other  FLT3 
TKIs. In vivo , TP-0903 delayed the outgrowth of leukemia and prolonged survival in xenograft models of 
FLT3-ITD+ AML. Collectively, our preclinical data demonstrate that TP -0903 has activity in de novo  and 
TKI-resistant FLT3 -ITD+ AML with the potential to be a best -in-class FLT3 TKI, and provide strong 
scientific premise to conduct a phase 1b/2 trial of TP -0903 in patients with FLT3 -ITD+ AML. Previous 
studies  have  shown  that responses  with single-agent  FLT3 TKI therapy  are generally short-lived, which  has 
led to the evaluation of several  TKIs in combination  with  chemotherapy  in phase  II/III trials [15, 18, 21, 49, 
50]. Therefore, we propose to evaluate TP -0903 as monotherapy for FLT3 -ITD+ AML patients with relapsed 
or refractory disease. We hypothesize that TP -0903 will have immediate clinical impact in FLT3 -ITD+  
AML . 
 
 
2. Patient Selection  
 
2.1. Eligibility Criteria 
 
 
2.1.1.  Patients age ≥18 with relapsed/refractory AML and the presence of FLT3 -ITD mutation.  
2.1.2.  Patients with secondary AML or therapy related disease (t -AML) are  eligible. 
2.1.3.  If the patient has co -morbid medical illness, life expectancy attributed to this must be 
greater than 6  months.  
2.1.4.  ECOG performance status  ≤2 
2.1.5.  Patients must have adequate organ function as defined  below: 
• Total bilirubin <2.0mg/dL unless due to Gilbert’s  disease  
• AST (SGOT)/ALT (SGPT) <2.5 X institutional upper limit of  normal  
• Cr clearance >50mL/min by Cockcroft -Gault  calculation  
• NYHA CHF Class II or better  
• Cardiac ejection fraction ≥ 40% 
 
2.1.6.  Female patients  of child -bearing potential  must  agree to use dual  methods  of contraception 
and have a negative serum pregnancy test at screening, and male patients must use an effective 
barrier method of contraception if sexually active with a female of child- bearing potential. 
Acceptable  methods  of contraception  are condoms  with  contraceptive  foam,  oral, implantable  or 
injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal 
gel, or a sexual  partner  who  is surgically sterilized or post -menopausal. For both  male and female 
patients, effective methods of contraception must be used throughout the study and for three months following the last dose. 
2.1.7.  Ability to understand and willingness to sign the written informed consent  document.  
2.1.8.  HIV infection without history of AIDS and sufficiently high CD4 cells (>400/mm3) and low 
20 of 59
IRB Protocol  Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 HIV viral loads (<30,000 copies/ml plasma) not requiring anti -HIV therapy are  eligible. 
 
2.2. Exclusion Criteria 
 
2.2.1.  Patients with acute promyelocytic leukemia.  
2.2.2.  Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for 
nitrosoureas  or mitomycin  C) prior  to entering the study.  Treatment  with  hydoxyurea  is permitted 
during cycle 1 to maintain WBC< 40,000/uL. 
2.2.3.  Patients receiving any other investigational agents or patients that have received other 
investigational agents within 14 days of  enrollment. 
2.2.4.  Patients with active CNS malignancy.  
2.2.5.  Major surgery within 2 weeks before Day  1. 
2.2.6.  Uncontrolled active infection. Patients with infection requiring parenteral antibiotics are 
eligible if the infection is  controlled. 
2.2.7.  Patients with significantly diseased or obstructed gastrointestinal tract.  
2.2.8.  Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive 
heart failure (New York Heart Association (NYHA) Class III or IV), unstable angina pectoris, 
myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction syst em 
abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically  relevant. 
2.2.9.  Patients with serious medical or psychiatric illness likely to interfere with participation in 
this clinical study.  
2.2.10.  Pregnant women or women who are breastfeeding are excluded from this study. 
Confirmation that the subject is not pregnant must be established by a negative serum β- human 
chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregn ancy 
testing is not required for post -menopausal or surgically sterilized  women.  
2.2.11.  Patients with advanced malignant solid tumors. 
2.2.12.  Patients who are not able to swallow capsules or tablets.  
2.3. Inclusion of Women and  Minorities 
 
 
Both men and women and members of all races and ethnic groups are eligible for this trial.  
 
   
21 of 59
IRB Protocol  Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 
No 
 Yes 
AlloHSCT 
(TP-0903 to be discontinued 
one week prior to admission)  
TP-0903 maintenance  
(Continue until loss of 
response/clinical benefit)  
Transplant Eligible?  
(for patients achieving CR/CRh/MLFS)  3. Treatment Plan  
 
TP-0903   MONOTHERAPY  FOR AML  PATIENTS  WITH FLT3  MUTATIONS  AND RELAPSED/REFRACTORY 
DISEASE  
AML patients with FLT3 mutations and relapsed/refractory disease are eligible to receive  TP-0903, at a 
starting dose of 50 mg daily as a single agent for days 1 -21 of a 28- day cycle. If the 50 mg dose does not  
meet the tolerability criteria, a lower dose level of 37 mg daily as a single agent for days 1 -21 of a 28-day 
cycle will be considered. 
 
 
 
Dose Level  TP-0903 (D1 -21) 
(mg/day PO)  
-1 25 
0 37 
1 50 
 
Patients may continue treatment indefinitely for as long as clinical benefit is achieved per the 
investigator’s judgment. Bone marrow examinations for disease response assessment will be mandated 
after the first cycle and at the end of treatment. Subsequent bone marrow examinations may be 
completed at the discretion of the treating physician.  
 
Schema:  
 
 
 
 
 
Clinical or hematologic  response  No clinical or hematologic respon se
Abbreviations: AlloHSCT, allogeneic hematopoietic stem cell transplant; CR, complete remission; 
CRh, complete remission with incomplete count recovery; MLFS, morphologic leukemia free state  TP-0903 days 1-21 
of 28 day cycle 
(up to 4 cycles)  
Off Treatment  
22 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 
3.1. Duration of Follow- up 
 
Patients will be followed monthly for treatment failure until the time of transplant or maintenance 
therapy, at which time they will go to clinical follow -up, followed every 3 months for up to 2 years from 
registration and then every 6 months for up to 5 years from registration until relapse or death. Patients who end treatment for reasons other than relapse or a subsequent AML treatment (exc luding 
transplant) will follow the same clinical follow -up schedule. Patients who relapse or receive a 
subsequent AML therapy (excluding transplant) will go to survival follow -up, followed every 6 months 
for 5 years from registration until death or the com pletion of the study. A survival follow -up visit can be 
conducted by phone or electronic contact with the patient or authorized representative. Please see the study calendar in Section 9 for details.  
 
3.2. Recommended supportive care treatment  and special considerations  
 
3.2.1. Nausea  
 Patients experiencing Grade ≤ 2 nausea or vomiting on any dose level should be instructed to take prochlorperazine by mouth 10 mg every 6 hours as needed.  Patients experiencing Grade 3 nausea on 
any dose level s hould be instructed to take 10 mg of prochlorperazine by mouth 30 minutes before 
their scheduled dose of TP -0903.  Additional doses of prochlorperazine may be given on an as needed 
basis (10 mg every 6 hours) .  If this is ineffective, patients may receive ondansetron 4 mg as an 
alternative, but will need an EKG checked prior to starting given the risk for increasing QTc interval.  
 
3.2.2 Diarrhea  
 
Patients experiencing  Grade ≤ 3 diarrhea should be instructed to take loperamide following each loose 
bowel movement (4 mg initial dose, followed by 2 mg after every loose bowel movement; maximum 
dose is 16 mg daily).  
 
 
4. Definition of Dose Limiting Toxicity (DLT)/Dosing Delays and Treatment  Modifications  
4.1. Definition of Dose Limiting Toxicity  (DLT) 
Drug-related toxicity in this population may be difficult to ascertain, given the aggressive nature of the 
underlying hematologic disease. Investigators will attempt to assign attribution of toxicities to each drug 
if possible. Toxicity attributed to any of the agents will be considered dose limiting. DLT will be assigned 
only to adverse events occurring with cycle 1 of therapy.  
Patients  who  experience dose  limiting toxicity  may  continue  on trial provided  that the toxicity  has resolved 
to at least Grade 2. The National Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE) version 5.0 (http://ctep.cancer.gov) will be used to characterize  toxicities.   However, any adverse 
reaction that leads t o dose reduction or withdrawal will be considered a DLT.  
Non He matologic:  
Any ≥ Grade 4 non -hematologic  toxicity will be considered a DLT.   
23 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Any non -Hy's law ≥ Grade 3 liver abnormality is a DLT unless it resolves within 72 hours.   
Any ≥ Grade 3 infection lasting more than 7 days in the absence of active AML is considered a DLT.  
Any ≥ Grade 3 bleeding with thrombocytopenia in the absence of active AML is considered a DLT.  
Any ≥ grade 3 non -hematologic toxicity not resulting directly from active leukemia is a DLT, with the 
exceptions of:  
• Alopecia 
• Line associated venous  thrombosis  
• Grade 3 fatigue, anorexia,  constipation  
• Grade  3 or 4 electrolyte disturbance that resolves within 24 hours  with  electrolyte correction  and 
is not clinically  significant, 
• Grade  3 nausea  or vomiting that does  not require hospitalization or support with  total  parenteral 
nutrition and resolves to < grade 2 within 72 hours  
 
The DLT observation period is defined as cycle 1 day 1 until completion of cycle 1 and will require that in 
the absence  of DLT,  patients  receive at least 14 of the 21 planned  doses  of TP-0903 during cycle 1 to be 
considered evaluable for the tolerability check of the phase 1b. In other words, a patient will be considered 
unevaluable for the tolerability check  and phase 1b component if a patient does not complete  the DLT 
observation  period due to reasons other  than  toxicity  (e.g.  progression). These patients will still be 
considered evaluable  and included in the denominator when analyzing efficacy  endpoints.  
 
Hematologic toxicity:  
Any ≥ Grade 4 neutropenia lasting more than 14 days past the end of the cycle (by day 42) in the absence 
of active AML should be considered DLT.  For patients with > 5% blasts, myelodysplastic changes, or 
evidence of disease by flow cytometry/cytogenetics, failur e to recover normal neutrophil count will not 
be considered DLT as this could be the result of persistent disease. Any patients who stop treatment prior to completing evaluation for the DLT observation period due to disease progression or refusal for further 
participation for reasons other than toxicity will be replaced for the purposes of dose - finding and safety  
evaluations.  
Other  events may  occur  which  do not meet the definition  of a DLT but are concerning  to the investigators 
and sponsor and may be then considered to be DLTs. Any other toxicities occurring during subsequent  
cycles after cycle 1  will lead to dose modifications as specified below. The National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (http://ctep.cancer.gov) will be 
used to characterize  toxicities. 
 
4.2. Dosing Delays/Dose  Modifications 
4.2.1 Dosing Delays/Dose Modifications for  DLTs:  
4.2.1.1  Non-hematologic DLT:  
Study treatment will be held for any patients experiencing a DLT . 
24 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Patients experiencing Grade ≥ 3 non -hematologic toxicity will have study treatment held until the toxicity resolves 
to NCI CTCAE  ≤ grade 1 or to the patient’s baseline values.  Patients may restart TP-0903 at the next lower dose 
level when the adverse e vent recovers to CTCAE  ≤ grade 1. If study treatment is restarted and another  non-
hematologic DLT (Grade ≥ 3 ) is encountered at the lower dose, the patient must be removed from the study. If the 
non- hematologic toxicity does not recur on re- challenge, the  dose level may be re -escalated at the initiation of 
next cycle at the discretion of the  investigator .  Study treatment will be discontinued permanently for any grade 4 
non-hematologic DLT.  
4.2.1.2  Hematologic DLT:  
After the 42 day period and confirmed  hematologic DLT:  If peripheral  blasts are absent  AND  bone marrow 
blasts are less than 5%, then the patient may restart study treatment on cycle 2 at the next lower dose 
level. 
After achieving CR, the dose level may be re -escalated at the initiation of next cycle at the discretion of 
the investigator. 
4.2.2 Dose Delays/Dose Modifications for  Non -DLTs  
4.2.2.1  Induction  
Patients experiencing non- DLT toxicities during induction related believed to be due to TP -0903 therapy 
that present a challenge  to medical  management  (i.e. grade  2 chronic  nausea, myalgia,  or fatigue)  should 
have their dose held until it falls to a level of grade 1 or < and then re -start at a -1 dose reduction in 
therapy. If this recurs at the lower dose, the patient will discontinue TP-0903 and be followed on the 
treatment regimen.  
4.2.2.2  Maintenance  
Non-hematologic toxicities  
Dose  modifications  due to TP-0903: Patients  experiencing grade 3 non-hematologic  toxicities  believed to 
be related to TP -0903 therapy (excluding correctable electrolyte abnormalities), select grade 2 toxicities 
(neurologic), or chronic grade 2 toxicity that presents a challenge to medical management (i.e. grade 2 
chronic nausea, myalgia, or fatigue) should have their TP -0903 dose held until this resolves to grade  1 or 
< and then  it may  be initiated at a dose level below the treating  dose. If this recurs at the lower dose, the 
patient will discontinue TP -0903 and be followed on the treatment  regimen. Patients experiencing a ny 
grade 4 non- hematologic toxicities will have treatment discontinued permanently .  
Hematologic toxicities  
TP0903 dose reductions  in subsequent cycles after  CR/CRi  is achieved (i.e., Subsequent cycles after being 
in CR/CRi for at least 1 cycle) will depend  on the counts  prior  to starting the preceding cycle . 
a) If prior to the previous cycle (for e.g., patient is starting C5, check the counts prior to starting 
C4) if the counts were: WBC ≥ 3.0 x109/L, ANC ≥ 1.5 x109/L, and platelets ≥ 75.0 x109/L (all 
three must apply), adjust the dose as follows, based on nadir counts of the prior cycle (per 
the e.g. above the prior cycle will be  C4): 
 
25 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Nadir Counts  % Dose  TP- 0903 in the 
Next Course  
ANC (x109/L)* Platelets (x109/L)*  
50% <0.5  <25.0  
* Dose reductions applies when either ANC OR Platelets are at these values  
 
4.3 General Administration Guidelines  
 
 
4.3.1 Missed or Vomited  Doses  
Missed or vomited doses will not be made up .  The patient will follow regular schedule starting the next study 
dosing day. All missed doses should be documented in the patient diary. If a dose is vomited within one hour of 
ingestion, it will be considered a missed dose and recorded as such on the patient diary.  If vomiting occurs more than 1 hour after dosing, it will still be considered a complete dose. 
 
 
 
5. Safety and Reporting  Requirements  
5.1. Assessment of  Safety  
Safety assessments will consist of monitoring and recording adverse events (and serious adverse events ); 
measurements of protocol -specified hematology, clinical chemistry, and other laboratory variables; 
measurement of protocol -specified vital  signs;  and other  protocol -specified tests  that are deemed critical 
to the safety evaluation of the study drug and should be consistent with institutional standards and Good 
Clinical Practice.  
5.2. Definitions  
 
 
5.2.1.  Adverse Events  (AE)  
An AE is any unfavora ble and unintended sign, symptom, or disease temporally associated with the use of 
an investigational (medicinal) product or other protocol -imposed intervention, regardless of attribution.  
For the purposes  of this clinical  study,  adverse  events  include  only  treatment- emergent  events which are 
either new or represent detectable exacerbations of pre -existing conditions.  
This includes the following:  
• Subjective or objective symptoms spontaneously offered by the subject and/or observed by the 
investigator or study staff including laboratory abnormalities of clinical  significance.  
• Any adverse events experienced by the subject through the completion of final study  procedures. 
• AEs not previously observed in the subject that emerge during the protocol -specified AE reporting 
period, including signs or symptoms associated with MCL that were not present before the AE reporting 
26 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 period 
• Complications that occur as a result of protocol-mandated interventions (eg, invasive procedures such 
as biopsies) 
The following are NOT  considered an adverse event:  
• Pre-existing condition: A pre-existing condition (documented on the medical history CRF) is not 
considered an AE unless the severity, frequency, or character of the event worsens during the study 
period.  
• Preplanned hospitalization: A hospitalization planned before signing the informed consent form is not 
considered an SAE, but rather a therapeutic intervention. However, if during the pre -planned 
hospitalization an event occurs, which prolongs the hospitalization or meets any ot her SAE criteria, the 
event will be considered an SAE. Surgeries or interventions that were under consideration but not performed before enrollment in the study will not be considered serious if they are performed after 
enrollment in the study for a condition that has not changed from its baseline level. Hospitalizations for 
social reasons or due to long travel distances are also not  SAEs.  
• Diagnostic  Testing and Procedures:  Testing and procedures  should  not to be reported as adverse  events 
or serious adverse events, but rather the cause for the test or procedure should be reported. 
 
5.2.2.  Serious Adverse Event  
The terms  “severe ” and “serious”  are not synonymous. Severity (or intensity)  refers to the grade of an AE 
(see below). “Serious” is a regulatory  definition and is based  on patient  or event outcome  or action  criteria 
usually associated with events that pose a threat to a patient’s life or functioning. Seriousness (not 
severity) serves as the guide for defining regulatory reporting obligations to applicable regulatory 
authorities. 
A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:  
• It results in death (i.e., the AE actually causes or leads to  death).  
• It is life- threatening (with regards to determining if an AE is serious, “life -threatening” is defined as an 
AE in which the subject was at risk of death at the time of the event. It does not refer to an event which 
hypothetically might have caused death if it were more severe. If either the investigator or  the Sponsor 
believes that an AE meets the definition of life-threatening, it will be considered  life-threatening.).  
• It requires or prolongs in -patient hospitalization. 
• It results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of 
the patient’s ability to conduct normal life functions).  
• It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the 
investigational product.  
• It is considered a significant medical event by the investigator based on medical judgment (e.g., may 
jeopardize the patient or may require medical/surgical intervention to prevent 1 of the outcomes listed 
27 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 above).  
5.2.3.  Severity  
Definitions found  in the Common  Terminology  Criteria for Adverse  Events  version 5.0 (CTCAE  v5.0)  will be 
used for grading the severity (intensity) of AEs. The CTCAE v5.0 displays Grades 1 through 5 with unique 
clinical descriptions of severity for each referenced AE. Should a patient experience any AE not listed in 
the CTCAE v5.0, the  following grading system should be used to assess  severity: 
• Grade 1 (Mild AE) – experiences which are usually transient, requiring no special treatment, and not 
interfering with the patient’s daily activities  
• Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience or concern to the 
patient, and which may interfere with daily activities, but are usually ameliorated by simple therapeutic measures  
• Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, significantly in terrupt the 
patient’s usual daily activity, and require systemic drug therapy or other  treatment 
• Grade 4 (Life -threatening or disabling AE) – experiences which cause the patient to be in imminent 
danger of  death  
• Grade 5 (Death related to AE) – experiences which result in patient  death  
 
 
5.2.4.  Suspected Adverse Reaction  
 
• A Suspected  Adverse  Reaction  is any adverse  event for which  there  is a “reasonable  possibility” that the 
drug caused the adverse event.  
• “Reasonable Possibility”, for the purposes of safety reporting, means there is evidence to suggest a 
causal relationship between the drug and the adverse event. Examples of evidence that would suggest a 
causal relationship between the drug and the adverse event  are: 
• A single occurrence of an event that is uncommon and known to be strongly associated with drug 
exposure (e.g., angioedema, blood dyscrasias, rhabdomyolysis, hepatic injury, anaphylaxis, and Stevens - 
Johnson Syndrome).  
• One or more occurrences of an event that is not commonly associated with drug exposure, but is 
otherwise uncommon in the population exposed to the drug (e.g., include tendon rupture or heart valve 
lesions in young adults,  or intussusception in healthy  infants).  If the event occurs  in association  with other 
factors strongly suggesting causation (e.g., strong temporal association, event recurs on rechallenge), a 
single case may be sufficiently persuasive; but often, more than one occurrence (from one or multiple 
studies) would be needed before the sponsor could make a determination of wh ether the drug caused 
the event.  
• An aggregate analysis of specific events that can be anticipated to occur in the study population 
independent of drug exposure. Such events include known consequences of the underlying disease or condition under investigation (e.g., symptoms or disease progression), or events unlikely to be related to 
the underlying disease or condition under investigation, but commonly occur in the study population 
28 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 independent of drug therapy (e.g., cardiovascular events in an elderly popul ation). An aggregate analysis 
(across studies)  will identify  those  events that occur  more frequently  in the drug treatment group  than  in 
a concurrent or historical control  group.  
5.2.5.  Unexpected  
An “unexpected” AE is an AE that is not listed in the Investigator  Brochure or is not listed at the specificity 
or severity that has been observed. For example, hepatic necrosis would be “unexpected” (by virtue of  
greater severity) if the Investigator Brochure referred only to elevated hepatic enzymes or hepatitis. 
"Unexpected" also refers  to AEs that are mentioned in the Investigator  Brochure  as occurring  with  a class 
of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the study drug under  inves tigation.  
5.3. Documenting and Reporting of Adverse Events (AEs) and Serious Adverse Events  (SAEs) 
 
The Sponsor -investigator is responsible for ensuring that all AEs and SAEs that are observed or reported 
during the study, as outlined in the prior sections, are recorded on the case report form (CRF). All SAEs 
also must be reported according to the OSU IRB guidelines.  
5.3.1.  Adverse Event Reporting  Period  
The AE reporting period for this study begins after first dose of study drug administration until 30 days after disc ontinuation of the study drug. All AEs and SAEs that are encountered during the protocol 
specified AE reporting period should be followed to resolution or until the investigator assesses the patient as stable, a new anti-cancer therapy is initiated, or the  patient is lost to follow up or withdrawals 
consent Resolution/stable means the subject has returned to baseline state of health or the Investigator does not expect any further improvement or worsening of the event.  
5.3.2.  Assessment of Adverse  Events  
Investigators will assess the occurrence of AEs and SAEs at all patient evaluation time points during the 
study. All AEs and SAEs whether volunteered by the patient, discovered by study personnel during 
questioning, or detected through physical examination, clinical ly significant laboratory test, or other 
means will be recorded in the patient’s medical record and on the AE CRF and, when applicable, on an 
SAE/Event reporting form.  
Each recorded AE or SAE will be described by its duration (i.e., start and end dates), s everity, regulatory 
seriousness criteria, if applicable, suspected relationship to the investigational product (see following 
guidance), and any actions taken.  
All deaths should be reported with the primary cause of death as the AE term, as death is typica lly the 
outcome of the event, not the event itself. The primary cause of death on the autopsy report should be the term reported.  
An SAE will qualify for expedited reporting to regulatory authorities if the SAE is considered a Suspected 
Adverse Reaction and is not listed in the current Investigator’s Brochure (i.e., an unexpected event). To 
ensure consistency of AE and SAE causality assessments, investigators should apply the following general guideline:  
Fatal  Adverse event resulted in death.  
29 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Unrelated  Another cause of the adverse event is more plausible; a temporal  
sequence cannot be established with  the onset of the adverse event 
and administration of the  investigational   product; or, a causal 
relationship is considered biologically implausible.  
Possibly 
Related  There is a clinically plausible time sequence between onset of the adverse event and administration of the investigatio nal product,  but 
the adverse  event  could  also be attributed to concurrent or underlying 
disease, or the use of other drugs or procedures. Possibly related 
should be used when the investigational product is one of several 
biologically plausible adverse even t causes.  
Definitely Related  The adverse event is clearly related to use of the investigational product.  
 
 
5.4. Procedures for Reporting Drug Exposure During Pregnancy and Birth  Events  
Before study enrollment, subjects must agree to take appropriate measures  to avoid pregnancy (See 
Section 4.2.4). Report  any pregnancy  that occurs in a patient or patient’s  partner  from  the time  of consent 
to 30 days after the last dose of study drug. Record any occurrence of pregnancy in the patient’s medical records and notify the treating physician within 24 hours of learning of the event. Abortion, whether 
therapeutic, elective or spontaneous, will be reported as an SAE.  
A patient must immediately inform the investigator if the patient or patient’s partner becomes pregnant from the time of consent to 30 days after the last dose of study drug. Any female patients receiving TP - 
0903 PO who become pregnant must immediately discontinue the drug. The investigator should counsel 
the patient, discussing any risks of continuing the pregnancy and any possible effects on the fetus. 
Although  pregnancy  itself is not regarded  as an AE, the outcome  will need  to be documented.  Report  any 
pregnancy that occurs in a subject or subject’s partner from the time of consent to 30 days after the last dose of study drug. Record any occurrence of pregnancy on appropriate case report form and send it to 
Sumitomo Dainippon Pharma Oncology, Inc. (S DPO) , or designee, within 24 hours of learning of the event. 
The pregnant female will be followed for outcome, which is defined as elective termination of the 
pregnancy, miscarriage, or delivery of the fetus. For pregnancies with an outcome of live birth, the 
newborn infant will be followed until 30 days old by completing the Pregnancy Report Form Part II. Any congenital anomaly/birth defect noted in the infant must be reported as an  SAE.  
5.5. Expedited Reporting Requirements for Serious Adverse  Events  
Instituti on/IND -Sponsor (OSU) of studies conducted under an IND must comply with the following safety 
reporting requirements. The Institution/IND -Sponsor (OSU) must submit each IND safety report in a 
narrative format or on FDA Form 3500A or in an electronic format that FDA can process, review and 
archive. A copy of this IND safety report must also be sent to Sumitomo Dainippon Pharma Oncology, Inc. 
(SDPO)  within 24 hours. The Institution/IND -Sponsor (OSU) must notify FDA and Sumitomo Dainippon 
Pharma Oncology, Inc. (SDPO)  of any serious, unexpected,  suspected  adverse  reaction observed during 
the conduct  of the study  as soon  as possible but in no case later than 15 calendar days after becoming 
aware of the occurrence. The Institution/IND - Sponsor (OSU) must notify FDA and Sumitomo Dainippon 
30 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 Pharma Oncology, Inc. (SDPO)  of any unexpected fatal or life-threatening suspected  adverse  reaction as 
soon  as possible,  but no later than  7 calendar  days  after  the Institution/IND - Sponsor’s (OSU)  receipt of 
the information. Upon  request from  the FDA or Sumitomo Dainippon Pharma Oncology, Inc. (SDPO)  
additional data or information that the agency or Sumitomo Dainippon Pharma Oncology, Inc. (SDPO)  
deems necessary, must be  reported as soon as possible but no later than 15 calendar days.  
All SAEs (initial and follow -up information) will be reported  on an Event Reporting form and submitted to 
the OSU IRB within 24 hours of the discovery of the event or information. All deaths should be reported 
with the primary cause of death as the AE term, as death is typically the outcome of the event, not the 
event itself. The primary  cause  of death  on the autopsy  repo rt should  be the term  reported.  If study  drug 
is discontinued because of an SAE, this information must be included in the SAE report.  
As noted  above,  in addition  to reporting  to the FDA, OSU will forward  completed  SAE and pregnancy  forms 
to representatives of Sumitomo Dainippon Pharma Oncology, Inc. (SDPO) . 
Address and phone number of person/sponsor responsible for SAE management at Sumitomo Dainippon 
Pharma Oncology, Inc. (SDPO). 
 SDPO Pharmacovigilance:  BBISafety@bostonbiomedical.com  
 
 
5.6. Routine Adverse Event  Reporting  
Adverse  events  which  do not meet  the definition of an SAE also require timely reporting  dependent  upon 
the grade of adverse event using CTCAE criteria, as defined by the protocol, attribution, and whether the 
event is expected or unexpected. All expedited adverse event reports must be reported to the CTO and 
OSU  IRB, in accordance  with  the IRB reporting  guidelines. These  reports  must  be included  in the in routine 
study data submission for the data safety monitoring  report.  
5.7. Type and Duration of Follow-up of Patients after Adverse  Events  
All AEs and SAEs that are encountered during the protocol-specified AE reporting period should be followed to resolution, or until the investigator assesses the patient as stable, a new anticancer therapy 
is initiated, or the patient is lost to follow -up or withdraws consent.  
5.8. Data Safety Monitoring Plan  (DSMP)  
The data  and safety  monitoring plan  for this phase  2 trial will involve  the continuous  evaluation  of safety, 
data quality and data timeliness. Investigators will conduct continuous review of data completeness and 
patient safety at the AML program meetings (twice monthly) and at the Phase 1/ 2 weekly meeting of 
phase I investigators and staff.  This review of the trials includes  discussion  of ‘milestone’ events  including 
encounters  of DLT or SAEs.  All discussions  will be documented  in the minutes. The PI of the trial will review 
toxicities and responses of the trial, where applicable, at these disease center meetings and determine if 
the risk/benefit ratio of the trial changes. Frequency and severity of adverse events will be reviewed by 
the PI and compared to what is known about the agent/device from other sources; including published 
literature, scientific meetings and discussions with the sponsors, to determine if the trial should be 
terminated before  completion.  Serious adverse  events  will also be reviewed monthly  and overall  summary 
reports submitted by the PI to the OSU -CCC Data and Safety Monitoring Committee (DSMC)  quarterly.  
 
 
31 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 6. Pharmaceutical  Information 
6.1 Drug  information 
 
6.1.1 Drug substance and description  
 
Generic name  TP-0903  
Chemical name  2-{[5 -chloro -2-({4 -[{4-methylpiperazin-1-yl)methyl]phenyl}amino)  
pyrimidin -4-yl]amino} -N,Ndimethylbenzene-1-sulfonamide mono -tartrate 
salt 
Other names  TP-0903, TP -0903 tartrate, HCL-2084, CCS -1589/STG -08 
Chemical formula  C28H36ClN 7O8S 
Molecular weight  666.15 Daltons  
Structure   
 
 
 
The drug  substance  is a white  crystalline solid with  a melting point  around 296°C.  The tartrate  salt is  soluble  
in water  in a pH dependent manner;  solubility increases with  decreasing  pH. In simulated  gastric fluid (SGF)  
the solubility is 3.64 mg/mL. In pH 6.5 USP buffer  solubility was poor,  at 0.013 mg/mL. The drug is also 
soluble in various commonly used and pharmaceutically acceptable organic  solvents.  
 
TP-0903 forms a stable polymorph that can be consistently prepared. The compound is hygroscopic, and 
will pick up as much as 12% of its weight in water, with about 3% observed in the drug substance at the 6-
month retest. Adding and subsequently  removing water  does  not alter the polymorph form or have an 
impact on compound  stability.  
 
Drug is supplied in 4 mg, 25 mg, and 100 mg dosage s trengths  in hard gelatin capsules (size #3).  
 
6.1.2 Preclinical absorption, distribution, metabolism, and  excretion  
 
6.1.2.1  Drug transporter  effects  
 
TP-0903 was tested in a bidirectional cell permeability assay using confluent monolayer of Caco - 2 cells in 
a 96-well based format. Fenoterol, propranolol and digoxin were used as controls. The efflux ratio (mean 
Papp A to B / mean Papp B to A) for TP -0903 was determined to be 1.49. Although mass recovery was low, 
this data  suggests  that TP-0903 is not a substrate  for P-glycoprotein and is a compound of moderate  
permeability. 
32 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
6.1.2.2  CYP450 effects  
TP-0903 was evaluated for the inhibition  of human  cytochrome  P450 isozymes using human  liver 
microsomes in the presence of NADPH. At 10 μM, TP -0903 inhibited the activity of only is oform 2C19 by 
more than 50% out of the isozymes selected for testing. The IC50 values were determined against all  the 
CYP isozymes used in the panel and, consistent with the percent inhibition data, only 2C19 was inhibited 
at a concentration lower than 10 μM (IC50 4.4 μM).  
 
6.1.2.3  Liver microsome stability 
 
The stability of TP -0903 in the presence of isolated microsomes  from three species (human, rat and dog) 
were determined. The concentration of TP -0903 was measured by liquid chromatography - tandem mass 
spectrometry (LC -MS/MS) with reference to a standard curve. The half -life of TP -0903 ranged from 4.3 
minutes in humans  to 7.2 minutes in dogs. 
 
6.1.2.4  Serum albumin  binding  
 
The serum albumin binding levels for TP -0903 were determined using human plasma in a dialysis plate -
based assay. The free fraction of TP -0903 was measured by LC -MS/MS, by reference to a standard curve,  
and w arfarin  was used  as a control.  Data showed  that TP-0903 has moderate  human serum albumin binding 
(7% unbound). Recovery of protein bound drug (80.3 %) indicated the binding was  reversible. 
 
6.1.2.5  pKa of  TP0903 
 The pKa values for TP -0903 were determined by titra tion using ultraviolet metric detection. The pKa  was 
determined in aqueous  buffer and separately in the presence of two co-solvents (80%  MeOH  and 60% 
DMSO). The final pKa  values were calculated as an average of the three values obtained under different 
solvent conditions with the exception of pKa 3, for which the pKa value determined in DMSO was 
excluded. The final pKa values for pKa1, pKa2, and pKa3 were 3.02, 3.96, and 7 .81, respectively. 
 
6.1.2.6  pH-dependent solubility of  TP0903  
 
The equilibrium solubility of TP-0903 tartrate  was determined in the following media:  pH 3.5, 4.5, 5.5, 6.5 
USP buffers,  0.1N  HCl, simulated gastric  fluid (SGF),  fasted  state  simulated  intestinal  fluid,  and fed state 
simulated intestinal fluid. As expected, based on the pKa determination, TP -0903 showed greatest 
solubility in acidic  media.  
 
6.2 Potential drug -drug interactions and concomitant  medications  
 Clinicians should  be aware  of the possibility of drug  interactions when  TP-0903 is co-administered with 
drugs that are inhibitors or inducers of CYP2C19. Clinicians should refer to the products label and to the  
drug  interaction website  (http://medicine.iupui.edu/clinpharm/ddis/main-table ). The website  listing 
Cytochrome P450 inhibitors and inducers is updated on an ongoing basis and can be found at Appendix 
A. 
 
33 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 6.3 Prohibited  therapies  
 
CYP2C19 substrates: Patients receiving CYP2C19 substrates prior to study treatment should be monitored  
closely. If possible, the investigator  should  cease  patient’s  treatment with  a CYP2C19 substrate prior to first 
dose, or at a minimum, switch to an alternative, but equivalent treatment that is not a CYP2C19 substrate. 
If a patient must remain on a CYP2C19 substrate, treatment with TP-0903 should proceed  cautiously  and 
the patient observed closely throughout  the duration  of the study.  (See Appendix A)  
Patients must not be taking H2 -receptor antagonists  such as cimetidine, ranitidine, and famotidine, or any 
proton pump inhibitors such as omeprazole, lansoprazole, esomeprazole and pantoprazole. Patients must stop these medications within 7 days prior to starting treatment. Antacids  such as calcium carbonate, 
aluminum hydroxide, sodium bicarbonate should be avoided just prior to administration of TP -0903.  
 
6.4. Study Drug  Management  
 
6.4.1.  TP-0903 Drug Product  
The study drug, oral TP -0903, is supplied by Sumitomo Dainippon Pharma Oncology, Inc. (SDPO)  as a 
powder in hard gelatin capsules (size #3) and is manufactured under current Good Manufacturing 
Practices (cGMP) for investigational use.  
TP-0903 capsules are formulated in 4-mg, 25 -mg and 100 -mg strengths. Further information is available 
in the 2019 DSUR, Regional Appendix 5, (page 64).  
 
6.4.2 Study Drug Dispensing and Accountability  
TP-0903 will be provided by the Sponsor  to study  centers  as an investigational  drug. The label and package 
for the drug product will be prepared in accordance with current regulatory requirements. The 
Investigator or designee will inventory and acknowledge receipt of all shipments  of study  drugs.  The study  
drugs  must  be kept  in a locked area with access  restricted  to designated study  personnel. 
 
An accurate and current accounting of the dispensing of the study drugs for each patient will be 
maintained  on an ongoing basis by a member  of the study  site staff  in a drug accountability  log or 
equivalent document and will be verified by the sponsor's study monitor. All drug supplies, including  
unused  study  drug,  must be accounted  for. A final  inventory  of the total  amount  of drug received at each 
study site against  the amount used and returned must be recorded in the study drug accountability log or 
an equivalent document. Inventory and dispense records must be readily available for inspection by the 
study monitor and/or auditor, and open to government inspection at  any time. Study drug destruction 
will be handled by the sites of open/used vials. Unopened  study  drug  vials should  be returned  to the 
Sponsor  or CRO  at the end of the study  after full drug accountability has been completed by the study  
monitor . 
6.4.3.  Storage at  Study  Center  
 
Study drug should be stored at room temperature. Protection from light is not necessary.  
 
34 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 6.4.4.  Accountability and Destruction of Investigational Medicinal  Product 
 
The Principal Investigator (or an authorized designee) at each participating institution must maintain a 
careful record  of the inventory  of the Investigational  medicinal  product  received using the Drug 
Accountability Form. The study drug will be destroyed as per site’s destruction policies and documentation of study drug destruction will be provided to the sponsor. Both used and unused study drug may be returned to Sumitomo Dainippon Pharma Oncology, Inc. (SDPO)  if requested.  
 
6.4.5.  Drug  Administration 
 
TP-0903 will be provided by Sumitomo Dainippon Pharma Oncology, Inc. (SDPO). OSU must request study 
drug by submitting an order form directly to the drug depot in order for the study drug to be shipped to 
the site pharmacy. The Investigator (or designee) will verify and acknowledge receipt of all study drug 
shipments by signing and returnin g all required forms. 
 
Study drug accountability records will be maintained at the site pharmacy and will be available for review 
by the study monitor during each monitoring visit and at the close out visit.  
 
All medication  must  be stored in a secure  area under  the proper  storage  requirements  with  access 
restricted to the site staff pharmacist or  designee(s).  
 The Investigational medicinal product should not be used for any purpose outside the scope of this 
protocol, nor can Investigational medicinal product be transferred or licensed to any party not participating in the clinical study.  Sumitomo Dainippon Pharma Oncology, Inc.’s (SDPO)  data for 
Investigational medicinal product are confidential and proprietary and shall be maintained as such by the Investigators.  
 
7. Measurement of  Effect  
 
7.1. Response Criteria 
Assessment  of clinical  response  will be made according to 2017 ELN AML  Recommendation  [1]. The major 
criteria for judging response will include physical examination and examination of blood and bone 
marrow.  All laboratory  studies  that are abnormal  prior  to study  will be repeated to document  the degree 
of maximal  response. 
Complete Remission without minimal residual disease (CRMRD -) 
• If studied pre-treatment, CR with negativity for a genetic marker by realtime quantitative polymerase chain reaction (RT -qPCR), or CR with negativity by multi -color flow cytometry 
[Sensitivities vary by marker tested, and by method used; therefore, test used and sensitivity of the assay should be reported; analyses should be done in  experienced laboratories (centralized 
diagnostics)  
Complete Remission (CR) * 
CR requires all of the following:  
35 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 • Bone marrow blasts  <5%  
• Absence of circulating blasts and blasts with Auer  rods.  
• Absence of extramedullary  disease  
• Absolute neutrophil count ≥1.0 x 109/L (1,000/μL).  
• Platelet count ≥100 x 109/L (100,000/μL).  
**MRD positive or unknown  
Complete Remission with hematologic improvement (CRh)**  
CRh meets all Criteria for CR except for residual thrombocytopenia and/or neutropenia defined as:  
• Bone marrow blasts <5%  
• Absence of circulating blasts on differential from peripheral blood (as determined by flow 
cytometry or blasts with morphologic Auer  rods)  
• Absence  of extramedullary disease  (disease  outside  of bone marrow not including  findings  on 
CT scan or oth er organ sites that have not been biopsied to confirm leukemia) 
• Absolute neutrophil count > 0.5 x 109/L (500/μL)  
• Platelet count > 50 x 109/L (50,000/μL)  
Complete Remission with incomplete blood count recovery (CRi)**  
CRi meets all CR criteria except for Re sidual neutropenia or thrombocytopenia:  
• Bone marrow blasts  <5%  
• Absence of circulating blasts and blasts with Auer  rods.  
• Absence of extramedullary  disease  
• Residual neutropenia <1.0 x 109/L (1,000/μL)  or 
• Residual Thrombocytopenia <100 x 109/L (100,000/μL)  
**If patients meet criteria for both CRh and CRi, they should be classified as CRh 
Morphologic leukemia free state  (MLFS)*** 
• Bone marrow blasts  <5%  
• Absence of blasts with Auer  rods.  
• Absence of extramedullary  disease  
• No hematologic recovery  required 
*** Marrow should not merely be “aplastic”;  at least  200 cells should  be enumerated  or cellularity should 
36 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 be at least  10% 
Partial Remission (PR)  
PR meets all hematologic criteria of CR:  
• Absolute neutrophil count ≥1.0 x 109/L (1,000/μL).  
• Platelet count ≥100 x 109/L (100,000/μL).  
     And 
• Decrease of bone marrow blast percentage to 5% to  25% 
• Decrease of pretreatment bone marrow blast percentage by at least  50%  
Stable Disease:  
• Absence of CRMRD -, CR, CRh, CRi, PR, MLFS; and criteria for PD not  met.  
Progressive Disease (PD):  
Evidence  for an increase in bone marrow blast  percentage  and/or  increase of absolute blast  counts  in the 
blood:  
• >50% increase in marrow blasts over baseline (a minimum 15% point increase is required 
in cases with <30% blasts at baseline;  or 
• Persistent marrow blast percentage of >70% over at least 3 months; without at least a 
100% improvement in absolute neutrophil count (ANC) to an absolute level [>0.5 x 109/L 
(500/μL), and/or platelet count to >50 x 109/L (50,000/μL) non -transfused];  or 
• >50% increase  in peripheral blasts  (WBC  x % blasts)  to >25 x 109/L (>25,000/μl)  (in the 
absence of differentiation syndrome)****;  or 
• New extramedullary  disease  
**** Certain targeted  therapies, for example,  those  inhibiting mutant  IDH proteins,  other  kinases or other 
targets  may  cause  a differentiation syndrome, i.e., a transient  increase  in the percentage  of bone marrow 
blasts and an absolute increase in blood  blasts;  in the setting  of therapy  with  such  compounds,  an increase 
in blasts may not necessarily indicate progressive disease. When this happens, it will be discussed with 
Beat AML Chief Medical Officer (CMO) on a case by case  bases.  
Treatment Failure  
Treatment failure will be classified as one of the following:  
• Primary refractory disease: No CRMRD- , CR, CRh, CRi and MLFS after defined period of 
time; excluding patients with death in aplasia or death due to indeterminate  cause  
• Death in aplasia: Deaths occurring ≥7 days following completion of initial treatment while cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 days of death,  
without evidence of persistent  leukemia  
• Death from indeterminate cause: Deaths occurring before completion of therapy, or <7 
37 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 days following its completion; or deaths occurring ≥7 days following completion  of initial 
therapy with no blasts in the blood, but no bone marrow examination  available.  
Recurrence  
Recurrence on this study is defined below.  
Recurrence for patients with prior morphological CRMRD -, CR, CRh, CRi or MLFS which is defined as:  
• Evidence  of morphologic  relapse with the reappearance  of leukemic  blasts  in the 
peripheral  blood or  ≥ 5% blasts in the bone marrow  not attributable  to any other  cause.  
In the setting  of recent  treatment, if there are no circulating blasts and the bone marrow 
contains 5-20% blasts, a bone marrow biopsy should be repeated within 1 week to 
distinguish relapse from bone marrow regeneration.  
• The reappearance of cytologically proven extramedullary disease also indicates  relapse. 
• New CNS disease or other new sites of extramedullary  involvement.  
It should be noted that reappearance of a cytogenetic or molecular abnormality would be considered a 
cytogenetic or molecular relapse. In the absence of morphologic relapse, this would not be considered a 
relapse. 
 
 
 
  
8. Correlati ve Studies  
 
8.1. Collection of  specimens.  
See section 9 for time points for blood and/or marrow sampling for pharmacokinetic (PK) and 
pharmacodynamics (PD studies). At each time point, peripheral blood and bone marrow aspirate for PD 
studies  will be collected. The samples will be processed at The OSUCCC Clinical Trials Processing Lab (CTPL) 
or the Leukemia Tissue Bank (LTB) Shared  Resources.  
 
 
8.2. Pharmacokinetic and pharmacodynamic studies in blood and  marrow.  
For standard techniques, only a brief summary is provided. For non -standard methods, additional 
information is provided on the technique to be utilized unless the method has been published. Blood 
samples for plasma PK will be transferred to the Pharmacoanalytical Shared Resource for bioanalytical 
analysis and estimation  of pharmacokinetic  parameters  by Dr. Mitch  Phelps  and Dr. Sharyn  Baker. Plasma, 
peripheral blood or bone marrow specimens for correlative PD studies will be transferred to Dr. Sharyn Baker’s lab for processing of cells for single cell RNA -seq an alysis of AML cells and bone marrow stromal 
cell in the Genomics Shared Resource (GSR), and multicolor flow cytometry and Fluorescence Activated Cell Sorting of AML cells b in the Analytical Cytometry Shared Resource (ACSR).  
38 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
 
8.2.2 Sampling for Plasma Pharmacokinetic and Pharmacodynamic studies  
All samples will be collected in green top (heparin) tubes. An intensive PK sampling scheme will be 
performed during course 1 in the patients enrolled during the phase I dose escalation phase. A limited sampling strategy will then be developed by Dr. Mitch Phelps for subsequent patients enrolled to the 
phase 2 portion of the trial. 
Sampling for TP -0903 plasma pharmacokinetic assessments will occur at the following times (cycle 1 
only):  
Day 1 and 5: just before dosing and at 0.5, 1, 2, 4, 8, and 24 hours after drug administration. The 24 -hour 
post -dose blood sample must be collected prior to the patient receiving TP -0903 on Day 2.  
Day 12: just before dosing and at 0.5, 1, 2, 4, 8, and 24 hours after drug administration (prior to the next 
dose).  
Plasma samples will be quantitated by a validated LC -MS/MS assay and pharmacokinetic parameters will 
be estimated using the software program Phoenix WinNonlin.  
Sampling for TP -0903 plasma pharmacody namics assessments for Axl, Gas6, FLT3 ligand and other 
cytokines/chemokines will occur at the following times: 
Day 1: Pre -dose then 2 and 24 hours after drug administration (prior to the next dose) 
Day 5 and 12: Pre -dose 
On the first day (pre- dose) prior to each subsequent dose 
Axl, Gas6, and FLT3 ligand will be determine by ELISA and other cytokines/chemokines will be determined 
using a multiplexed Luminex assay. 
 
 
8.2.3. Sampling for Blood and Bone Marrow Pharmacodynamic Studies  
All patients  will have  serial peripheral  blood  sampling  where  cells are isolated at screening, day 5, at count 
recovery, at day 28 of each  subsequent cycle (when  available)  and at time  of relapse (in responding 
patients). Samples will be collected in green top (heparin tubes).  
Patients will also have serial bone marrow sampling at screening, day 5, the time of remission marrow, and at time of relapse.  
In these samples we will assess the following*:  
• In baseline samples and paired baseline/relapse samples, patterns of sensitivity and resistance 
patterns will be assessed by genomic, epigenomic, and transcriptomic profiling. 
• In paired baseline and day 5 samples, differentially expressed genes  in bone marrow  stromal  cells 
and AML cells will be assessed by single -cell RNA -eq. 
39 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
 • In paired  baseline and day 5 samples, changes in pAXL, pFLT3, pSTAT5, pAURKA, cell cycle 
distribution, apoptosis will be assessed by multicolor flow  cytometry.  
• In paired  baseline and day 5 samples, changes  in metabolites and the flux of carbon  derived from 
either isotopically labeled glutamine (13C,15N -Gln),  glucose (13C6- Glc) or other  substrates (e.g.  palmitate, 
pyruvate, aspartate), will be determined using UPLC -MS/MS  analysis  
* Correlatives studies will be prioritized as above, depending on the amount of sample that is available 
for analysis.  
** If a significant potential somatic, acquired mutation is identified patients will not be returned these 
results. However, if in the future  it is decided that a germline analysis  should  be done,  we will amend  the 
protocol  as appropriate and patients will be given the option to have these germline mutation results 
returned and undergo CLIA -certified germline testing for the potential pathogenic mutation.
40 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
9. Study  Calendars 
Baseline evaluations are to be conducted within 14 da ys prior to start of protocol therapy. Labs must be done prior to treatment on day 1 and 
maybe used for screening purposes as well. Scans and X -rays must be done <4 weeks prior to the start of therapy. In the event that the patient’s 
condition is deteriora ting, laboratory evaluations should be repeated within 48 hours prior to initiation of the next cycle of therapy.  
TP-0903 monotherapy, (Cycle 1 only)  
 
  
Screening*  Induction                    
   
   
        End-of 
Treatment10 Follow -
up11 
 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10  D11 D12 D13 D14 D15 D16 D18 D21 D28    
Medical History  x                    x  
Complete Physical 
exam and ECOG PS  x 
           
  
  
    x x 
Weight and BSA   
x x    x       
  
  
  x x x  
Symptom directed 
physical evaluation   
 x    x       
x  
  
  x  x  
Vitals signs1 x 
x    x       
x  
  
   x x x 
12-Lead 
Electrocardiogram 
(ECG)2  
  
x x           
  
  
    x  
Serum pregnancy test3 x 
           
  
  
    x **if fertile 
female only   
CBC4 x x    x       x       x x x 
Complete Serum 
chemistry5  
 
x x    x       
x  
  
   x x x 
Coagulation tests (PT 
and PTT )   
 
x x    x       
x  
  
    x  
TP-0903 dosing in 
Clinic/ Home/Inpa tient6  
x x x x x x x x x x x x x x x x x x    
Bone Marrow (BM) 
aspiration and biopsy7  
 
x     x       
  
  
   x   
41 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 
  
* *Treatment may begin on the same day as screening.  
1  Vital signs including blood pressure [BP], heart rate [HR], respiratory rate [RR], temperature [T] pulse oximetry (POX) and w eight will be assessed prior to 
administration of TP -0903.     
2  ECGs: to be performed in the supine position at screening and day 1 of the first cycle.  
3 Applies to women of childbearing potential (WOCP) only.  WOCP must have a negative pregnancy test within 2 weeks prior to the initiation of therapy.  
4 Complete Blood count with differential will be performed about twice weekly during induction and then as clinically indicated.  
5 Complete serum chemistries includes: Sodium, Potassium, Chloride, Bicarbonate, Creatinine, BUN, Glucose,  Phosphorus,  Albumi n, Total bilirubin, SGOT 
(AST), S GPT (ALT), Alkaline phosphatase  and  LDH Women of childbearing potential must have a negative pregnancy test within 2 weeks prior to the initiation 
of therapy.  
6 TP-0903 will be administered per section 3.  
7 Bone marrow (BM) core biopsy and aspiration which will include cytogenetics, flow cytometry, targeted mutational analyses and morphologic assessment.  
Aspirate (10ml) only is required on day 5 of cycle 1 for correlative studies.  Cycle 1, day 28 BM examination will require 10 ml aspirate to be collected for 
correlative studies.  All the specimens for correlative studies will be processed at the OSU Leukemia Tissue Bank.  Aspiration only may be acceptable for 
patients with BM biopsy that falls out of the window, provided AML diagnosis is unequivocal.  
8Logistical issues that preclude patient visit on days noted will be allowed under special circumstances but must be discussed with the PI. Should such 
occasions arise, evaluations should be done as soon as feasible, preferably within 24 -48hours  
9 Correlatives studies to be performed per section 8.2 (+/ - 1 day). All patients will have serial peripheral blood sampling where cells are isolated at screening, 
day 5, day 12, at count recovery, at day 28 of each subsequent cycle (when available) and at time of relapse (in responding p atients). Samples will be collected 
in green top (heparin tubes).  
10 End of Treatment visit , if applicable,  is to be performed 30+7 days following patient last drug administration.  
11Patients will be followed monthly for treatment failure until the time of transplant or maintenance therapy, at which time they will go to clinical follow -up, 
followed every 3 months for up to 2 years from registration and then every 6 months for up to 5 years from registration until  relapse or death. Patients who 
end treatment for reasons other than relap se or a subsequent AML treatment (excluding transplant) will follow the same clinical follow -up schedule. Patients 
who relapse or receive a subsequent AML therapy (excluding transplant) will go to survival follow -up, followed every 6 months for 5 years fro m registration 
until death or the completion of the study.  A survival  follow-up visit can be conducted by phone or electronic contact with the patient or authorized 
representative. Adverse event and 
Toxicity evaluation8 x     x       
x  
  
  x x x  
Correlative Studies9 x 
x    x       
x  
  
   x   
42 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
   
TP-0903 monotherapy (Cycles 2-4 and maintenance) 
 
 
 
 
           
 
           
 
 
 
1
 ECGs to be completed on day 1 of cycles 2, 3 and 4 only.  Subsequent ECGs for cycle 5 and later may be completed based on clinical judgment.  
2 TP-0903 will be administered per section 3.  
3 Bone marrow (BM) core biopsy and aspiration which will include cyt ogenetics, flow cytometry, targeted mutational analyses and morphologic 
assessment is required only on Cycle 4, day 28 .   BM examination on cycle 4, day 28 will require  10 ml aspirate to be collected for correlative 
studies.  However, if the patient has persistent cytopenias or if there is concern for relapse, BM examination can be completed sooner based on 
clinical judgment.  All the specimens for correlative studies will be processed at the OSU Leukemia Tissue Bank.  Aspiration only may be acceptable 
for p atients with BM biopsy that falls out of the window, provided AML diagnosis is unequivocal. 
4Logistical issues that preclude patient visit on days noted will be allowed under special circumstances but must be discussed with the PI. Should  Cycles 2 -4 and maintenance         
   
   
        End of 
Treatment6 Follow -
up7 
 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10  D11 D12 D13 D14 D15 D16 D18 D21 D28    
Weight and BSA  
x           
  
  
   x x x 
 Physical examination  
x     x      
  
  
    x  
Vitals signs 
x     x      
x  
  
   x x x 
12-Lead 
Electrocardiogram 
(ECG)1 
x           
  
  
    x  
CBC 
x     x      x       x x x 
Complete Serum 
chemistry 
x     x      
x  
  
   x x x 
Coagulation tests (PT 
and PTT )  x           
x  
  
    x  
TP-0903 dosing in 
Clinic/ Home/Inpa tient2 x x x x x x x x x x x x x x x x x x    
Bone Marrow (BM) 
aspiration and biopsy3 
           
  
  
   x   
Adverse event and 
Toxicity evaluation4 x           
x  
  
   x x  
Correlative Studies5 
           
  
  
   x   
43 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
  such occasions arise, evaluations should be done as soon as feasible, preferably within 24 -48hours .  Toxicity assessments on day 12 are only 
required for cycles 2 -4.  Cycles 5 and beyond require toxicity assessment only on days 1 and 2. 
5 If applicable, peripheral blood wi ll be collected for correlative studies at day 28 of each subsequent cycle (when available) and at time of relapse 
(in responding patients). Samples will be collected in green top (heparin tubes). 
6 End of Treatment  visit , if applicable,  is to be performed 30+7 days following patient last drug administration.  
7Patients will be followed monthly for treatment failure until the time of transplant or maintenance therapy, at which time they will go to clinical 
follow-up, followed every 3 month s for up to 2 years from registration and then every 6 months for up to 5 years from registration until relapse 
or death. Patients who end treatment for reasons other than relapse or a subsequent AML treatment (excluding transplant) will  follow the same 
clinical follow -up schedule. Patients who relapse or receive a subsequent AML therapy (excluding transplant) will go to survival follow -up, followed 
every 6 months for 5 years from registration until death or the completion of the study.  A survival follow -up visit can be conducted by phone or 
electronic contact with the patient or authorized representative . 
44 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
  
10. Statistical  Considerations  
Overview 
 
This phase 1b/2 study will be conducted in adult relapsed/refractory AML patients with FLT3 mutations  
 treated with TP -0903 monotherapy.  
 
The study  will open to accrual initially to confirm tolerability of TP -0903 monotherapy using 50 mg daily. 
If in the first 6 patients treated, tolerability is not confirmed, then an additional 6 patients will be treated 
using 37 mg daily. Once  a tolerable dose level of TP-0903 monotherapy  is confirmed,  full accrual  to the 
phase 2 portion of the trial will continue. Design details described below assume that TP- 0903  
monotherapy  of 50 mg daily  will be found tolerable.  
Confirmation of Tolerability  
 
TP-0903 monotherapy has been evaluated in solid tumors and found to be safe at a dose level of 50 mg 
daily. Although we do not anticipate  any safety  challenges in patients  with AML  at this dose level, an early 
tolerability assessment will be included for the first 6 patients enrolled based on a standard Rolling 6 
design. If at most one in 6 patients has a DLT (See Section 4), then TP -0903 monotherapy at 50 mg daily 
will be considered safe and we will proceed wit h full accrual of the phase 2 study. If however TP -0903 
monotherapy at 50 mg daily does not have acceptable toxicity in the first 6 patients, then an additional 6 
patients will be treated at a lower dose level of TP -0903 at 37 mg daily, and the same rule will be used to 
confirm tolerability. Once a tolerable dose level is confirmed, enrollment can continue to the phase 2 component at that dose level. 
Phase 2 
 
At the confirmed tolerable dose level, TP -0903 monotherapy will be assessed for efficacy in a phase  2 
component. Efficacy data from patients treated at the confirmed tolerable dose level during the tolerability check will be utilized in the phase 2 portion of the trial. Efficacy will be assessed using 
Simon’s optimal two -stage phase 2 clinical trial des ign constraining type I and II errors to 10%.  
 
The primary endpoint is the composite CR rate (CR/CRh), defined according to the 2017 ELN AML 
Recommendation. All eligible patients who start therapy will be considered evaluable for the primary 
endpoint and included  in the denominator  when calculating the composite  CR rate.  In relapsed/refractory 
adult patients with AML and FLT3 mutations, the ADMIRAL phase 3 study reported a composite CR rate of 34% with the FLT3 inhibitor gilteritinib, which led to improved overall survival (REF). We will therefore 
test the null hypothesis  that the composite  CR rate with  TP-0903 is 30% versus the alternative  hypothesis 
that it is 55%.  By design,  if 13 or more  of 31 evaluable patients  achieve CR/CRh,  then  there  will be sufficient 
evidence to warrant  further  study  of TP-0903 in this patient  population. An interim analysis will occu r 
after 13 patients have response determined. If 4 or fewer of 13 evaluable patients achieve CR/CRh, then the study will be terminated early. If 5 or more of 13 evaluable patients achieve CR/CRh then enrollment 
will continue as planned for all 31 evaluable patients. The probability of early termination under the null 
hypothesis is 0.65. 
Toxicity will continue to be monitored throughout the phase 2 component, and a rule for excessive 
toxicity will be continuously applied. The monitoring rule will be evaluated during the first cycle of 
45 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 therapy and will be based on the number of patients with a DLT out of the total number of patients 
treated (See Table Below). The number of patients with a DLT that would warrant accrual suspension 
corresponds to a high posterior probability that the true DLT probability is greater than an acceptable 
level (i.e., Pr( pi > 0.25 | data) > 0.95), where the posterior probab ility is determined from a Beta - 
Binomial distribution with Beta (1, 1) as the prior on p i. For example, if 9 patients have been treated in 
the phase 2 study, and 5 or more patients have a DLT, then this is sufficient evidence of excessive 
toxicity and accrual will be suspended while data are reviewed more closely, and a decision will be made 
to modify or close the  study.  
Table: Excessive Toxicity Rule, following the Confirmation of Tolerability in the First 6 Patients  
 
Number of  
Patients  7 8 9 10 11 12 13 14 15 16 
Number with 
DLT 4 4 5 5 6 6 6 7 7 7 
Number of 
Patients  17 18 19 20 21 22 23 24 25 26 
Number with 
DLT 8 8 8 9 9 9 10 10 10 11 
Number of 
Patients  27 28 29 30 31      
Number with 
DLT 11 11 12 12 12      
 
 
Accrual  
 
In the phase 1b component, we expect 6 patients and a maximum of 12 patients. In the phase 2 
component, we will over -accrue by roughly 10% and target an accrual of 34 patients. Overall, we plan to 
accrue 40 -46 patients. Based on past accrual of FLT3- mutated AML patients at OSU, we would anticipate 
accruing 1 -2 patients per month, with accrual completed in 2 -3 years.  
Analysis of Secondary Endpoints  
 
The degree of response will be summarized. Among eligible patients who achieve CR/CRh, disease-free survival (DFS) will be calculated. DFS is defined from the date of first CR/CRh until the first date of 
relapse/progression or death from any cause. Any patient without progression or death will be censored 
at the last date of clinical assessment. Further, patients who go to transplant prior to a progression  will be 
censored at that time.  The number  and proportion  of patients  going to transplant  prior to progression will 
be provided. Overall survival (OS) will be calculated for all eligible patients who start therapy. OS will be 
defined from the treatment start date until the date of death from any  cause  or date  last known  alive. Both  
time -to-event endpoints  will be summarized  by the Kaplan-Meier method. Associations between baseline 
variables and clinical outcome will be descriptive in nature due to  the small  sample sizes,  primarily using  
46 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 graphical  displays to identify patterns  and trends.  
 
The maximum grade of each type of adverse event will be recorded for each patient and summarized.  
Treatment-related adverse  events, defined as possibly,  probably  or definitely related to study treatment 
per NCI CTCAE v5.0 will be summarized separately. In addition, reasons for treatment discontinuation  and 
number  of TP-0903 cycles  received will be summarized  and used  to assess tolerability. All patients  who  have 
received at least  one dose of study  drug will be evaluable for safety  and tolerability assessments.  
Initial analysis of plasma PK data will include standard compartmental and non -compartmental methods 
using Phoenix WinNonlin version 6.3 to generate estimates for relevant parameters (CL/F, V/F, Cmax, t1/2, 
AUC, etc.). Descriptive statistics will include means, standard deviations, and frequencies will be 
computed  for all variables.  Relationships  between continuous  variables will be performed  using standard 
linear correlation and linear regression. Relationships  between PK parameters  such  as Cmax  and AUC  with 
response will be performed using standard t -tests or Wilcoxon rank sum tests  and illustrated using 
boxplots or other graphical displays. Differences in cytokines/chemokines, kinase signaling, and gene 
expression between days 1 and 5 will be evaluated using paired t -tests or Wilcoxon signed rank tests. 
Values will be log transformed as appropriate to reflect biologic plausibility. Patterns of sensitivity and resistance will be purely  descriptive. 
 
11. Ethics and Regulatory  Requirements  
 
 
11.1. Patient  Protection  
This study will be conducted according to the principles outlined by the Declaration of Helsinki and all 
applicable amendments; the International Conference of Harmonization 29 Version 05/21/2013 (ICH) Guidelines for Good Clinical Practice; the U.S. Food and Drug Administration (FDA) regulations regarding the conduct of clinica l trials and the protection of human subjects; the Institutional Review Board (IRB), 
any applicable local health authority, and the Ethics Committee requirements.  
 
11.2. Patient  Information  
Before entry into the trial all eligible patients will receive written patient information describing the aim 
of the study, as well as probable and possible side effects and risks. Oral information from one of the 
investigators or a delegated person at the institution will also be given, and the patient must have the 
opportun ity to ask questions, and to consider participation together with his/her family members if 
applicable. It will be emphasized that the participation is voluntary and that it is the right of the patient to  
refuse  further participation  in the study  whenever he/she wants  and that this will not influence his/her 
subsequent care. 
11.3. Informed  Consent  
Patient / Legally acceptable representative (LAR) (as applicable) written consent must be obtained 
according to local Institutional and/or University Human Experimentat ion Committee requirements and 
must conform to the ICH guidelines for Good Clinical Practice, prior to any study -specific screening 
procedures and trial entry. The written informed consent form should be signed and personally dated by the patient or by the  patient’s legally acceptable representative. A copy of the signed informed consent 
will be given to the patient  or patient’s  legally authorized  representative. The original  signed consent must 
be maintained by the investigator at OSU available for inspection by the sponsor, or regulatory authority 
47 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 at any time. The IRB will review the consent form for  approval.  
11.4. Ethics Board Approval  
This study must obtain the approval of the protocol, the informed consent document and any other 
material used to inform the patient about the nature of the trial by a properly constituted IRB. The trial 
should not start until a copy of this written approval has been received by the Investigator. The 
Investigator will supply with a copy of the IRB approval letter stating that the study protocol and any 
subsequent amendments and informed consent have been reviewed and approved. The investigator or 
designee will be responsible for obtaining annual IRB re-approval throughout the duration of the study 
including at completion or  termination.  
Any changes to this protocol made by the Investigator must be in the form of a written amendment and 
the amendment will be appended to the protocol. Approval of amendments by the IRB is required prior to their implementation, unless there are overriding safety reasons.  
Upon completion of the trial, the Investigator must provide the IRB and sponsor with a summary of the 
trial’s outcome.  
Annual Report:  The PI will submit annual reports to the sponsor and FDA.  
 
12. Documentation, Record Access and Ma intenance of Study  Records 
 
 
12.1. Documentation of Patient’s Participation  
A statement acknowledging the participation of a patient in this clinical trial must be documented in the 
patient's medical records along with the signed  ICF. 
12.2. Source  Documentation  
Source  records  are original documents,  data,  and records  (e.g.,  medical  records, raw data  collection forms, 
pharmacy dispensing records, recorded data from automated instruments, laboratory data) that are 
relevant to the clinical trial. The Investigator will prepare and maintain adequate and accurate source 
documents. These documents are designed to record all observations and other pertinent data for each 
patient enrolled in this clinical trial. Source records must be adequate to reconstruct all data transcribed 
onto the Case Report Forms  (CRFs).  
12.3. Regulatory Requirements  
Before  the investigational drug  is shipped to the Investigator,  the Investigator  will provide  to the sponsor 
with a copy of the IRB approval letter stating that the study protocol and any subsequent amendments 
and informed consent form have been reviewed and  approved.  
12.4. Patient Confidentiality and Access to Source  Data/Documents  
 
 
12.4.1.  Patient  Identification 
A sequential unique identification number will be attributed to each patient registered in the trial. This 
number will identify the patient and must be included on all case report forms. A patient will not be 
identified by name, only by his/her initials. The patient’s name or any identifying information will not 
appear in any reports published as a result of this study. In order to avoid identification errors, patient’s 
initials and date of birth (as permitted by the ethics board) will also be reported on the study forms. Any 
48 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 research information obtained about the patient in this study will be kept confidential. However, 
information obtained from individual patient’s participation in the study may be disclosed with his/her  
consent to the health care  providers  for the purpose of obtaining  appropriate medical  care.  The patient’s 
medical records/charts, tests will be made available to the sponsor Sumitomo Dainippon Pharma 
Oncology, Inc. (SDPO) , the US FDA, and  the IRB and any other  regulatory authorities.  This is for the purpose  
of verifying information obtained for this study. Confidentiality will be maintained throughout the study 
within the limits of the  law. 
A patient’s name will not be given to anyone except the researchers conducting the study, who have 
pledged  an oath  of confidentiality. All identifying  information will be kept  behind locked doors,  under  the 
supervision of the study Principal Investigator and will not be transferred outside of the  hospital. 
A patient may take away his/her permission to collect, use and share information about him/her at any 
time. If this situation occurs, the patient will not be able to remain in the study. No new information that 
identifies the patient will be gathered after that date. However, the information about the patient that 
has already been gathered and transferred may still be used and given to others as d escribed above in 
order to preserve the scientific integrity and quality of the study.  
12.5. Confidentiality of the  Study  
Data generated as a result of this study are to be available for inspection on request by local health authority auditors, the Sponsor’s Stu dy Monitors and other personnel (as appropriate) and by the IRB. 
The Investigator  shall  permit sponsor,  authorized  agents  of the sponsor,  and regulatory  agency  employees 
to enter and inspect any site where the drug or records pertaining to the drug are held, and to inspect all source  documents. The protocol  and other  study  documents  contain  confidential  information and should 
not be shared or distributed without the prior written permission of  sponsor. 
Release of research  results should  preserve the privacy  of medical  information and must  be carried out in 
accordance with Department of Health and Human Services Standards for Privacy of Individually Identifiable Health Information, 45 CFR  164.508.  
 
12.6. Registration of Clinical  Trial  
Prior to the first patient being registered/enrolled into this study, the Sponsor will be responsible for ensuring that the clinical trial is registered appropriately to remain eligible for publication in any major 
peer-reviewed journal, adhering to the guidelines put forth by the International Committee of Medical 
Journal Editors (ICMJE).  
 
12.7. Maintenance of Study  Records  
To enable evaluations and/or  audits  from  Regulatory  Authorities, the Investigator  agrees to keep records, 
including  the identity  of all participating  patients  (sufficient information to link records,  CRFs  and hospital 
records), all original signed informed consent forms, copies of all CRFs, source documents, and detailed records of treatment  disposition.  
 
According  to 21 CFR 312.62(c), the Investigators  shall  retain record s required  to be maintained under  this 
part for a period of two years following the date a marketing application is approved for the drug for the 
indication for which it is being investigated. If no application is to be filed or if the application is not 
approved for such indication, the Investigator shall retain these records until two years after the 
49 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 investigation is discontinued and the FDA is  notified.  The Investigator  must  retain  protocols,  amendments,  
IRB approvals, copies of the Form FDA 1572, signed and dated consent forms, medical records, case report 
forms, drug accountability records, all correspondence, and any other documents pertaining to the 
conduct of the  study.  
If the investigator  relocates,  retires, or for any reason  withdraws from  the study, then  the Sponsor  should 
be prospectively notified. The study records must be transferred to an acceptable designee, such as another investigator, another institution, or to the Sponsor. The investigator must obtain the Sponsor’s 
written permission befo re disposing of any  records.  
 
13. Administrative Procedures  
 
 
13.1. Protocol Deviations and Violations 
All violations or deviations are to be reported to the site’s IRB (as per the ethics board’s guidelines). All 
IRB correspondence is to be forwarded to the sponsor. The site must notify the sponsor immediately of 
any protocol violations.  
13.2. Premature Discontinuation of the  Study  
The Sponsor  reserves the right to discontinue the trial for any reason  but intends  only  to exercise  this right 
for valid scientific or administrative reasons. After such a decision, the Investigators must contact all 
participating patients immediately after notification. Standard therapy and follow -up for patients will be 
assured and, where required by the applicable regulatory requirement(s), the relevant regulatory authority(ies) will be  informed.  
The IRB will be informed promptly and provided with a detailed written explanation for the termination 
or suspension.  
As directed by the Sponsor, all study materia ls must be collected and all CRFs completed to the greatest 
extent possible in the case of a premature discontinuation of study. 
 
 
14. References  
 
 
1. Dohner, H., et al., Diagnosis and management of AML in adults: 2017 ELN recommendations 
from an international expert panel. Blood, 2017. 129(4): p.  424-447.  
2. Byrd, J.C., et al., Pretreatment cytogenetic abnormalities are predictive of induction success, 
cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid 
leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002. 100(13): p. 
4325-36. 
3. Grimwade, D., et al., The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998. 92( 7): p.  2322-33.  
4. Schlenk, R.F., et al., Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 2008. 358(18): p.  1909-18.  
5. Pemmaraju, N., et al., FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an 
era? Cancer, 2011. 117(15): p.  3293-304.  
50 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 6. Hart, S., et al., SB1518, a novel macrocyclic pyrimidine -based JAK2 inhibitor for the treatment of 
myeloid and lymphoid malignancies. Leuke mia, 2011. 25(11): p.  1751-9.  
7. Reindl, C., et al., Point mutations in the juxtamembrane domain of FLT3 define a new class of 
activating mutations in AML. Blood, 2006. 107(9): p.  3700-7.  
8. Thiede, C., et al., Analysis of FLT3 -activating mutations in 979 patients with acute myelogenous 
leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. 
Blood, 2002. 99(12): p.  4326-35. 
9. Adolfsson, J., et al., Identification of Flt3+ lympho -myeloid stem cells lacking erythro - 
megakaryocytic potential a revised road map for adult blood lineage commitment. Cell, 2005. 
121(2): p.  295-306.  
10. Breccia, M., et al., Comorbidities and FLT3 -ITD abnormalities as independent prognostic 
indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol, 2009. 27(3): p. 
148-53.  
11. Whitman, S.P., et al., Absence of the wild -type allele predicts poor prognosis in adult de novo 
acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res, 2001. 61(19): p. 7233-9.  
12. Cortes, J.E., et al., Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS -like tyrosine kinase 3 -internal tandem 
duplication status. J Clin Oncol, 2013. 31 (29): p.  3681-7.  
13. Fischer, T., et al., Phase IIB trial of oral Midostaurin (PKC412), the FMS -like tyrosine kinase 3 
receptor (FLT3) and multi- targeted kinase inhibitor, in patients with acute myeloid leukemia and 
high-risk myelodysplastic syndrome with either wild- type or mutated FLT3. J Clin Oncol, 2010. 
28(28): p.  4339-45.  
14. Stone, R.M., et al., Patients with acute myeloid leukemia and an activating mutation in FLT3 
respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005. 105(1): p. 54 - 
60. 
15. Uy, G.L., et al., A phase 2 study incorporating sorafenib into the chemotherapy for older adults 
with FLT3 -mutated acute myeloid leukemia: CALGB 11001. Blood Adv, 2017. 1 (5): p.  331-340.  
16. Stone, R.M., et al., Midostaurin plus  Chemotherapy for Acute Myeloid Leukemia with a FLT3 
Mutation. N Engl J Med, 2017. 377(5): p.  454-464.  
17. Levis, M., et al., In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytoto xic effects. Blood, 2004. 104(4): p. 1145 - 
50. 
18. Levis, M., et al., Results from a randomized trial of salvage chemotherapy followed by 
lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 2011. 117(12): p. 3294- 301.  
19. Jain, P., et al., Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.  
Leuk Lymphoma, 2014. 55(6): p. 1337-44. 
20. Ravandi, F., et al., Phase I/II study of combination therapy with sorafenib, idarubicin, and 
cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol, 2010. 28(11): p. 1856- 
62. 
21. Serve, H., et al., Sorafenib in combination with intensive chemotherapy in elderly patients with 
acute myeloid leukemia: results from a randomized, placebo -controlled trial. J Clin Oncol, 2013. 
31(25): p. 3110-8.  
22. Wander, S.A., M.J. Levis, and A.T. Fathi, The evolving role of FLT3 inhibitors in acute myeloid 
leukemia: quizartinib and beyond. Ther Adv Hematol, 2014. 5(3): p.  65-77.  
23. Larrosa-Garcia, M. and M.R. Baer, FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Mol Cancer Ther, 2017. 16(6): p.  991-1001.  
51 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 24. Smith, C.C., et al., Characterizing and Overriding the Structural Mechanism of the Quizartinib- 
Resistant FLT3 "Gatekeeper" F691L Mu tation with PLX3397. Cancer Discov, 2015. 5(6): p. 668 - 
79. 
25. Baker, S.D., et al., Emergence of polyclonal FLT3 tyrosine kinase domain mutations during 
sequential therapy with sorafenib and sunitinib in FLT3 -ITD-positive acute myeloid leukemia. Clin 
Cancer R es, 2013. 19(20): p.  5758-68.  
26. Kindler, T., D.B. Lipka, and T. Fischer, FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 2010. 116(24): p.  5089-102. 
27. McMahon, C.M., et al., Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed 
and Refractory FLT3 -Mutated Acute Myeloid Leukemia. Blood, 2017 ASH Abstract, 2017. 
130(295).  
28. Zhang, H., et al., Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3 -D835 
Inhibitor Crenolanib. Blood 2015 ASH Annual Meeting, 2015 126(2468).  
29. Panetta, J.C., et al., Population pharmacokinetics of crenolanib, a type I FLT3 inhibitor, in patients with relapsed/refractory AML . 2015, Blood. p.  3695.  
30. Patel, J.P., et al., Prognostic relevance of integrated genetic profiling in acute myeloid  leukemia.  
N Engl J Med, 2012. 366(12): p. 1079-89.  
31. Papaemmanuil, E., et al., Genomic Classification and Prognosis in Acute Myeloid Leukemia. N 
Engl J Med, 2016. 374(23): p.  2209-2221. 
32. McMahon, C.M., et al., Mechanisms of acquired resistance to gilteritinib therapy in relapsed and 
refractory FLT3-mutated acute myeloid leukemia. Blood, 2017.  130. 
33. Janning, M., I. Ben -Batalla, and S. Loges, Axl  inhibition: a potential road to a novel acute myeloid 
leukemia therapy? Expert Rev Hematol, 2015. 8 (2): p.  135-8.  
34. Park, I.K., et al., Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential 
therapeutic target. Blood, 2013. 121(11): p.  2064-73.  
35. Park, I.K., et al., Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3 - 
targeted therapy in acute myeloid leukemia. L eukemia, 2015. 29(12): p.  2382-9.  
36. Ben-Batalla, I., et al., Axl, a prognostic and therapeutic target in acute myeloid leukemia 
mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013. 122(14): 
p. 2443-52.  
37. Ju, H.Q., et al., ITD mu tation in FLT3 tyrosine kinase promotes Warburg effect and renders 
therapeutic sensitivity to glycolytic inhibition. Leukemia, 2017. 31(10): p.  2143-2150. 
38. Gallipoli, P., et al., Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia 
unmasked by FLT3 tyrosine kinase inhibition. Blood, 2018. 131(15): p.  1639-1653.  
39. Gregory, M.A., et al., Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid 
leukemia. Exp Hematol, 2018. 58: p.  52-58. 
40. Mollard, A., et al., Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase 
Inhibitors. ACS Med Chem Lett, 2011. 2 (12): p.  907-912.  
41. Myers, S.H., V.G. Brunton, and A. Unciti -Broceta, AXL Inhibitors in Cancer: A Medicinal Chemistry 
Perspective. J Med Chem, 2016. 59(8): p.  3593-608. 
42. Smith, C.C., et al., Validation of ITD mutations in FLT3 as a therapeutic target in human acute 
myeloid leukaemia. Nature, 2012. 485(7397): p.  260-3.  
43. Zimmerman, E.I., et al., Crenolanib is active against models of drug -resistant FLT3 -ITD-positive 
acute myeloid leukemia. Blood, 2013. 122(22): p.  3607-15.  
44. Albers, C., et al., The secondary FLT3 -ITD F691L mutation induces resistance to AC220 in FLT3 - 
ITD+ AML but retains in vitro sensitivity  to PKC412 and Sunitinib. Leukemia, 2013. 27(6): p. 1416 - 
8. 
52 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 45. Man, C.H., et al., Sorafenib treatment of FLT3 -ITD(+) acute myeloid leukemia: favorable initial 
outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a 
D835 muta tion. Blood, 2012. 119(22): p.  5133-43.  
46. Chu, S.H. and D. Small, Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat,  2009.  
12(1 -2): p. 8 -16. 
47. Sexauer, A., et al., Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in 
FLT3/ITD AML. Blood, 2012. 120(20): p.  4205-14. 
48. Vernieri, C., et al., Targeting Cancer Metabolism: Dietary and Pharmacologic  Interventions. 
Cancer Discov, 2016. 6 (12): p. 1315-1333. 
49. Knapper, S., et al., A randomized assessment of adding the kinase inhibitor lestaurtinib to first - 
line chemotherapy for FLT3 -mutated AML. Blood, 2017. 129(9): p.  1143-1154.  
50. Ravandi, F., et al., Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013. 121(23): p.  4655-62.  
53 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
  
Appendix A. Cytochrome P450 Drug Interaction Table  
 
Physicians should be aware of the possibility of drug interactions when TP -0903 is co -administered with drugs that are inhibitors or inducers of  CYP2C19. 
Physicians should refer to the products label and to the drug interaction website provided below. The website listing Cytochrome P450 inhibitors and 
inducers  is updated on an ongoing  basis and can be found  at http://medicine.iupui.edu/clinpharm/ddis/main -table. Below is a snapshot of the website as 
of August 2018. Attention should be focused on the 2C19 column . Please note that the website also lists substrates of  CYP2C19.  
 
Cytochrome P450 Drug Interaction Table  
Substrates         
1A2 2B6 2C8 2C9 2C19  2D6 2E1 3A 4,5,6  
amitriptyline  
caffeine2  clomipramine  
clozapine  
cyclobenzaprine  
duloxetine  
estradiol  fluvoxamine  
haloperidol  
imipramine N -DeMe  
mexiletine  nabumetone  
naproxen  
olanzapine  
ondansetron  
phenacetin1→  
acetaminophen →  
NAPQI propranolol  riluzole  ropivacaine  
tacrine2  artemisinin  
bupropion1  
cyclophosphamide  efavirenz1  ifosphamide  
ketamine  
meperidine  methadone  
nevirapine  
propafol  
selegiline  
sorafenib  
 amodiaquine  
cerivastatin  
paclitaxel  
repaglinide  sorafenib  
torsemide   
 NSAIDs:  
diclofenac  ibuprofen  
lornoxicam  
meloxicam S -
naproxen→  
Norpiroxicam  
suprofen  
 
Oral Hypoglycemic Agents:  
tolbutamide  
glipizide   Angiotensin II Blockers:  
losartan  
irbesartan  
 
Sulfonylureas:  PPIs:  
esomeprazole  lansoprazole  
omeprazole2  pantoprazole  
 Anti-epileptics:  
diazepam→  
Nor phenytoin(O)  
S-mephenytoin1  
phenobarbitone  
 
amitriptyline  
carisoprodol  
citalopram  
chloramphenicol  clomipramine  
clopidogrel  
cyclophosphamide  
hexobarbital  tamoxifen  
 
Beta Blockers:  
carvedilol  S-metoprolol  propafenone  
timolol  
 
Antidepressants:  
amitriptyline  clomipramine  
desipramine  
fluoxetine  imipramine  paroxetine  
venlafaxine   
Antipsychotics:  
haloperidol  
perphenazine  
risperidone→9 -OH  Anesthetics:  
enflurane  
halothane  
isoflurane  methoxyflurane  
sevoflurane  acetaminophen→  
NAPQI  
aniline2  benzene  
chlorzoxazone1  
ethanol  
N,N-dimethylformamide  theophylline→8 -
OH  
 Macrolide  
clarithromycin  
erythromycin2 (not NOT telithromycin   Anti-arrhythmics:  
quinidine→3 -OH  
 Benzodiazepines:  
alprazolam  
diazepam→3OH  
midazolam1 triazolam2  
 Immune:  
cyclosporine  
tacrolimus (FK506)  
 HIV  
indinavir  
54 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 theophylline2  
tizanidine  
triamterene  
verapamil  (R)warfarin  
zileuton  zolmitriptan  
 glyburide  
glibenclamide  glipizide  glimepiride  tolbutamide  
 amitriptyline  celecoxib  fluoxetine  fluvastatin  
glyburide  
nateglinide  
phenytoin -4-
OH2  
rosiglitazone  
tamoxifen  
torsemide  
valproic acid  
S-warfarin  
zakirlukast  
 imipramine N -
DeME  
indomethacin  
labetalol R - 
mephobarbital  
moclobemide  
nelfinavir  nilutamide  primidone  
progesterone  
proguanil  
propranolol  
teniposide R- warfarin→8-OH  
voriconazole  
 
 thioridazinezuclopenthix
ol alprenolol  
amphetamine  
aripiprazole  atomoxetine  
bufuralol1  
chlorpheniramine  
chlorpromazine  
clonidine codeine (→O-
desMe)  
debrisoquine2  
dexfenfluramine  
dextromethorphan1  
donepezil  duloxetine  
encainide  
flecainide  fluvoxamine  
lidocaine  metoclopramide  
methoxyamphetamine  
mexiletine  
minaprine  
nebivolol  nortriptyline  
ondansetron  
oxycodone  
perhexiline  
phenacetin  
phenformin  
promethazine  
propafenone  
propranolol  
risperidone  
sparteine  nelfinavir  
ritonavir  
saquinavir  
 Prokinetic:  
cisapride  
 Antihistamines: astemizole chlorpheniramine 
terfenadine2  
 
Calcium  
amlodipine  
diltiazem  
felodipine  
lercanidipine  
nifedipine2  
nisoldipine  
nitrendipine  
verapamil  
 HMG:  atorvastatin  
cerivastatin  
lovastatin  
NOT  
NOT  
simvastatin  
 
Steroid  
estradiol  hydrocortisone  
progesterone  
testosterone1  
55 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 tramadol   
Miscellaneous:  
alfentanil  aprepitant  
aripiprazole  
boceprevir  
buspirone  
carbamazepine  
cafergot  
caffeine→TMU  
cilostazol cocaine  
codeine-N- demethylation  
dapsone  
dexamethasone  
dextromethorphan2  
docetaxel  domperidone  
eplerenone  
fentanyl  
finasteride  
gleevec  haloperidol  irinotecan  
LAAM  
lidocaine  
methadone  
nateglinide  
nevirapine  
ondansetron  
pimozide  propranolol  
quetiapine  
quinine  
56 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 risperidone  
romidepsin  
salmeterol  
sildenafil  sirolimus  
sorafenib  
sunitinib  
tamoxifen  
taxol  
telaprevir  terfenadine  
torisel  
trazodone  
vemurafenib  
vincristine  
zaleplon  
ziprasidone  
zolpidem   
Inhibitors         
1A2 2B6 2C8 2C9 2C19  2D6 2E1 3A 4, 5, 6  
fluvoxamine  
ciprofloxacin  cimetidine  amiodarone  
efavirenz  
fluoroquinolones  
fluvoxamine  
furafylline1  
interferon  
methoxsalen  
mibefradil  
ticlopidine   clopidogrel  
thiotepa  
ticlopidine  voriconazole  gemfibrozil2  
trimethoprim2  
glitazones  montelukast1  
quercetin1  
 fluconazole2  
amiodarone  
efavirenz  fenofibrate  fluconazole  
fluvastatin  
fluvoxamine2  
isoniazid  
lovastatin  
metronidazole  
paroxetine  
phenylbutazone  
probenicid  
sertraline  PPIs:  
esomeprazole  
lansoprazole  omeprazole2  pantoprazole  
 Other:  
chloramphenicol  cimetidine  felbamate  
fluoxetine  fluvoxamine  
indomethacin  
isoniazid  
ketoconazole  bupropion  
cinacalcet  
fluoxetine  paroxetine  
quinidine1  
duloxetine  
sertraline  terbinafine  amiodarone  
cimetidine  
celecoxib  
chlorpheniramine  
chlorpromazine  
citalopram  
clemastine  diethyl -
dithiocarbamate2 disulfiram  
 HIV Antivirals:  
indinavir  
nelfinavir ritonavir  clarithromycin  
itraconazole1  
ketoconazole  
nefazodone  
saquinavir  
suboxone  
telithromycin  
aprepitant  
erythromycin  
fluconazole  
grapefruit juice  
57 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 sulfamethoxazol
e  
sulfaphenazole1  
teniposide  
voriconazole  
zafirlukast  
 
 modafinil  
 
Oral contraceptives:  
oxcarbazepine  
probenicid  
ticlopidine2  topiramate  
voriconazole  clomipramine  
cocaine  
diphenhydramine  
doxepin  
doxorubicin  
escitalopram  halofantrine  
haloperidol  histamine H1 receptor antagonists  
hydroxyzine  
levomepromazine  methadone  
metoclopramide  mibefradil  
midodrine  
moclobemide  
perphenazine  
promethazine  
ranitidine  
reduced -haloperidol  
ritonavir  
ticlopidine  tripelennamine  
 verapamil2 
diltiazem  
cimetidine  amiodarone  
chloramphenicol  
boceprevir  
ciprofloxacin  delaviridine diethyl - 
dithiocarbamate  
fluvoxamine  
gestodene  
imatinib  
mibefradil  
mifepristone  
norfloxacin  
norfluoxetine  
starfruit  
telaprevir  voriconazole  
 
Inducers         
1A2 2B6 2C8 2C9 2C19  2D6 2E1 3A 4, 5, 6  
broccoli  
brussel sprouts  
carbamazepine  
char -grilled meat  
insulin 
methylcholanthrene1  
modafinil  artemisinin  
carbamazepine  
efavirenz  
nevirapine  
phenobarbital  
phenytoin  
rifampin  
 rifampin  carbamazepine 
enzalutamide  
nevirapine phenobarbital 
rifampin secobarbital  St. John's Wort  
 carbamazepine 
efavirenz enzalutamide  
norethindrone NOT pentobarbital prednisone rifampicin  dexamethasone  
rifampin  
 Ethanol  
isoniazid   HIV Antivirals: 
efavirenz  
nevirapine  
barbiturates carbamazepine  
enzalutamide glucocorticoids modafinil 
58 of 59
IRB Protocol Number:  2020C0078  
IRB Approval date:  03/11/2021  
Version:  03/03/2021   
 nafcillin  
beta -
naphthoflavone1  
omeprazole1  
rifampin  
tobacco  
 
 ritonavir  
St. John's Wort  
   oxca rbazepine 
phenobarbital2 phenytoin2 pioglitazone  
rifabutin  
rifampin  
St. John's Wort  
troglitazone  
 
 
59 of 59